

1 BOTTINI & BOTTINI, INC.  
2 Francis A. Bottini, Jr. (175783)  
fbottini@bottinilaw.com  
3 Yury A. Kolesnikov (271173)  
ykolesnikov@bottinilaw.com  
4 7817 Ivanhoe Avenue, Suite 102  
La Jolla, California 92037  
5 Telephone: (858) 914-2001  
Facsimile: (858) 914-2002

6  
7 *Attorneys for Plaintiffs*

8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF CALIFORNIA  
SAN JOSE DIVISION

LEE VOSS, SEBASTIANO D'ARRIGO, ) Lead Case No. 14-cv-1581-LHK  
JAMES DIBIASE, and MARIE DIBIASE, ) (Consolidated with 14-cv-2523-LHK and  
on behalf of themselves and all others ) 14-cv-3214-LHK)  
similarly situated and derivatively on )  
behalf of MARVELL TECHNOLOGY )  
GROUP, LTD., )  
Plaintiffs, )  
vs. )  
SEHAT SUTARDJA, JUERGEN )  
GROMER, JOHN G. KASSAKIAN, )  
ARTURO KRUEGER, RANDHIR )  
THAKUR, PANTAS SUTARDJA, WEILI )  
DAI, and DOES 1-20, )  
Defendants, )  
- and - )  
MARVELL TECHNOLOGY GROUP, )  
LTD., )  
Nominal Defendant.)

---

## Table of Contents

1	<b>SUMMARY OF THE ACTION .....</b>	1
2	JURISDICTION AND VENUE.....	5
3	PARTIES.....	6
4	I.    Plaintiffs .....	6
5	II.    Nominal Defendant.....	6
6	III.    The Individual Defendants .....	6
7	CONSPIRACY, AIDING AND ABETTING, AND CONCERTED ACTION.....	12
8	DUTIES OF THE INDIVIDUAL DEFENDANTS .....	13
9	SUBSTANTIVE ALLEGATIONS.....	21
10	I.    Marvell Was Founded by the Sutardja Brothers and Dai .....	21
11	II.    The Once and Future King and Queen of Marvell: Defendants Sutardja and Dai's History of Self-Dealing and Dishonesty, Blessed and Approved by a Supine Board .....	22
12	III.    The Individual Defendants' History of Alleged Theft of Intellectual Property .....	28
13	IV.    The Individual Defendants Cause Marvell to Willfully Infringe Patents Owned by Carnegie Mellon University.....	29
14	V.    Materially False and Misleading Statements Issued During the Relevant Period .....	39
15	THE UNJUST COMPENSATION PAID TO THE INDIVIDUAL DEFENDANTS .....	50
16	THE THREAT TO THE PAYMENT OF DIVIDENDS TO MARVELL'S CURRENT SHAREHOLDERS.....	59
17	CLASS ACTION ALLEGATIONS .....	60
18	DERIVATIVE ALLEGATIONS.....	62
19	I.    The Derivative Claims are Authorized Under <i>Foss v. Harbottle</i> Because Defendants' Wrongdoing has Infringed Upon the Shareholders' Personal Rights.....	62
20	II.    The Derivative Claims are Authorized Under <i>Foss v. Harbottle</i> Because Defendants' Conduct Was <i>Ultra Vires</i> .....	63

1	III. The Derivative Claims are Authorized Under <i>Foss v. Harbottle</i> Because the “Fraud on the Minority” Exception Is Applicable.....	65
2	CAUSES OF ACTION .....	66
3	Count I	
4	Breach of Fiduciary Duty	
5	Against All Individual Defendants.....	66
6	Count II	
7	Breach of Fiduciary Duty	
8	for Failing to Maintain Adequate Internal Controls	
9	Against All Individual Defendants.....	67
10	Count III	
11	Unjust Enrichment	
12	Against Defendants Sehat Sutardja, Pantas Sutardja, and Weili Dai .....	68
13	Count IV	
14	Breach of Duty of Honest Services	
15	Against Defendants Sehat Sutardja, Pantas Sutardja, and Weili Dai .....	68
16	PRAYER FOR RELIEF .....	69
17	DEMAND FOR JURY TRIAL.....	71
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		

1 Plaintiffs, by and through their attorneys, allege the following upon  
 2 information and belief, except as to those allegations concerning Plaintiffs, which  
 3 are alleged upon personal knowledge. Plaintiffs' information and belief is based  
 4 upon, among other things, Plaintiffs' counsel's investigation, including a review of  
 5 legal and regulatory filings, press releases, and media reports about Nominal  
 6 Defendant Marvell Technology, Group, Ltd. ("Marvell" or the "Company").

7 **SUMMARY OF THE ACTION**

8 1. This is a direct shareholder class action on behalf of shareholders of  
 9 Marvell, and a shareholder derivative action on behalf of Marvell seeking to remedy  
 10 wrongs committed by the Individual Defendants (as defined in paragraph 24 below).  
 11 During the Relevant Period (2003 through 2013), certain Marvell officers and  
 12 directors violated state and federal law by breaching their fiduciary duties, engaging  
 13 in fraud and dishonest conduct by willfully infringing federal patents held by  
 14 Carnegie Mellon University ("CMU"), unjustly enriching themselves at the expense  
 15 of the Company, and wasting corporate assets.

16 2. The Individual Defendants' conduct has damaged Marvell shareholders  
 17 directly by jeopardizing and interfering with shareholders' rights to dividends. The  
 18 Individual Defendants' conduct has also damaged Marvell by causing a judgment of  
 19 \$1,169,140,271 to be entered in December 2012 against Marvell and in favor of CMU  
 20 in federal court in Pennsylvania. That court made additional findings that the  
 21 infringement was willful, thus entitling CMU to enhancement damages of up to  
 22 three times the amount of the verdict. On March 31, 2014, United States District  
 23 Judge Nora Barry Fischer in Pittsburgh, where CMU is based, increased the  
 24 judgment to approximately \$1.54 billion to include such enhancement damages.<sup>1</sup> In  
 25 her ruling, Judge Fischer said "enhanced damages" were justified against Marvell

---

26 27 28 <sup>1</sup> The total amount of the judgment, which includes the original judgment, the  
 enhanced damages, and two years of post-judgment interest, was \$1,535,889,387.60.  
 Such amount does not include any amounts that Marvell will be obligated to pay under  
 the judgment for ongoing royalties.

1 and its Marvell Semiconductor unit because CMU showed that Marvell deliberately  
 2 copied its patents through “known willful infringement.” The total judgment of  
 3 approximately \$1.54 billion is equal to 1.23 times the sum of the original \$1.17  
 4 billion jury verdict from December 2012, plus \$79.6 million for alleged  
 5 infringements that the jury did not consider because it did not have access to recent  
 6 financial information at the time.

7       3.     In issuing the order for enhanced damages, Judge Fischer stated:  
 8 “This award is sufficient to penalize Marvell for its egregious behavior and to deter  
 9 future infringement activities.”

10     4.     The judgment has required Marvell to post a bond to secure the  
 11 judgment. Since the original judgment was entered, Marvell has filed multiple  
 12 unsuccessful motions to have the judgment set aside. In August 2013, Judge Nora  
 13 Fischer denied Marvell’s motion for a mistrial. By order dated September 23, 2013,  
 14 Judge Fischer denied Marvell’s motion for judgment notwithstanding the verdict.

15     5.     Moreover, on February 24, 2014 Marvell filed the following Form 8-K  
 16 with the SEC disclosing that the CMU judgment has impaired or may impair its  
 17 ability to pay future dividends to its shareholders:

18     On February 20, 2014, Marvell announced that it had declared the  
 19 payment of its quarterly dividend of \$0.06 per share to be paid on March  
 20 27, 2014 to all shareholders of record as of March 13, 2014.  
 21 Developments in the CMU litigation could affect Marvell’s ability to pay  
 22 the dividend on March 27, 2014 under Bermuda law, where Marvell is  
 23 incorporated. In such event, the payment of the dividend could be  
 24 delayed until such time as Marvell can meet statutory requirements  
 under Bermuda law. The payment of future quarterly cash dividends is  
 subject to, among other things, the best interests of its shareholders, its  
 results of operations, cash balances and future cash requirements,  
 financial condition, statutory requirements of Bermuda law, and other  
 factors that the board of directors may deem relevant.

25     6.     The CMU verdict has a high probability of materially and adversely  
 26 affecting Marvell and its cash flows, including its ability to declare and pay  
 27 dividends, as disclosed by the Company in its Annual Report filed on March 27,  
 28

1 2014:

2 On March 6, 2009, Carnegie Mellon University (“CMU”) filed a  
 3 complaint in the U.S. District Court for the Western District of  
 4 Pennsylvania naming Marvel Semiconductor, Inc. and us as defendants,  
 5 and alleging patent infringement. CMU has asserted U.S. Patent Nos.  
 6 6,201,839 and 6,438,180 (collectively, the “CMU patents in suit”), which  
 7 relate to read-channel integrated circuit devices and the HDD products  
 8 incorporating such devices. A jury trial began on November 26, 2012.  
 9 On December 26, 2012, a jury delivered a verdict that found the CMU  
 10 patents in suit were literally and willfully infringed and valid, and  
 11 awarded past damages in the amount of \$1.17 billion. ***Due to the***  
 12 ***finding of willfulness during post-trial proceedings, the judge***  
 13 ***could enhance the damages by an amount up to triple the***  
 14 ***damages awarded by the jury at trial. In addition, CMU has***  
 15 ***disclosed in its post-trial motions that it is seeking pre-***  
 16 ***judgment interest up to \$322 million, post-judgment interest,***  
 17 ***supplemental damages, attorneys' fees, and an injunction***  
 18 ***and/or ongoing royalties.*** Post-trial motions were heard on May 1  
 19 and 2, 2013. On June 26, 2013, the District Court denied CMU’s post-  
 20 trial motion for attorney fees without prejudice. On August 23, 2013, the  
 21 District Court denied our motion for mistrial. On September 23, 2013,  
 22 the District Court denied our motion for judgment as a matter of law or a  
 23 new trial on non-infringement, invalidity and other non-damages issues  
 24 as well as our motion for reduced damages. On the same day, the District  
 25 Court granted-in-part CMU’s motion for a finding of willful infringement  
 26 and enhanced damages, reserving its further rulings on any enhancement  
 27 of the verdict for a forthcoming opinion. On January 14, 2014, the  
 28 District Court denied our post-trial motion on laches. We believe that  
 there are strong grounds for appeal and we intend to vigorously  
 challenge the District Court’s judgment via an appeal to the U.S. Court of  
 Appeals for the Federal Circuit in Washington, D.C., but there is no  
 guarantee that we will be successful on appeal. Please see “Note 10 –  
 Commitments and Contingencies” of our Notes to the Consolidated  
 Financial Statements set forth in Part II, Item 8 of this Annual Report on  
 Form 10-K for a more detailed description of a number of litigation  
 matters we are currently engaged in. Should the District Court in the  
 CMU case grant an injunction or if we are required to pay most or all of  
 the damages awarded by the jury after all appeals have been exhausted,  
***this could have a material adverse effect on our business,***  
***financial condition, results of operations and cash flows.***

29 We plan to appeal the final judgment issued by the District Court  
 30 in the CMU litigation, regardless of the dollar amount of the final  
 31 judgment. The parties are currently engaged in discussions before a  
 32 Special Master concerning the bonding of the judgment pending appeal.  
 33 During October 2013, we entered into indemnity agreements with a  
 34 consortium of insurers that would potentially provide financial assurance  
 35 that each of the insurers will be indemnified by us should a loss occur

1 under a surety bond. As of February 1, 2014 and as of the date of this  
 2 filing, no final judgment has been issued and no surety bond has been  
 3 issued. Therefore, these indemnity agreements have had no impact to our  
 4 Consolidated Balance Sheets as of February 1, 2014. We expect that  
 5 under a surety bond, the surety companies would agree to guarantee to  
 6 the District Court our payment of a specific amount, to be determined.  
 7 However, the terms of any surety bond arrangements have not been  
 8 finalized, and we cannot be certain that a surety bond will be available to  
 9 us in sufficient amount to cover the full amount of a final judgment or on  
 10 commercially reasonable terms. ***If we cannot obtain a surety bond  
 11 in sufficient amount or on commercially reasonable terms, or  
 12 if the District Court in the CMU litigation does not approve  
 13 alternative arrangements to stay execution of the judgment  
 14 pending our appeal, our business could be harmed. For  
 15 example, if, under a surety bond, we must post our cash, cash  
 16 equivalents and short term investments as collateral, we may  
 17 be restricted from using such assets in the operation of our  
 18 business and such assets would be classified as restricted  
 19 cash in future filings.***

20       7. The CMU patents currently encompass all of Marvell's HD chips and  
 21 the per-chip royalty will result in roughly a 20% hit to operating margins on  
 22 Marvell's HD controller business. Since the HD controller business makes up  
 23 approximately 50% of Marvell's sales, the ongoing impact to earnings will be highly  
 24 material, and could result in a 25% reduction in net earnings for Marvell as a whole  
 25 going forward.

26       8. In addition to the CMU verdict, the Individual Defendants' willful  
 27 violation of CMU's patents has further damaged Marvell by significantly increasing  
 28 its legal expenses. As disclosed in Marvell's 2012 Annual Report, filed in March  
 2013: "General and administrative expense increased by \$7.9 million in fiscal 2013  
 compared to fiscal 2012. The increase was primarily attributed to an increase in legal  
 expenses, a significant portion of which related to the CMU trial towards the end of  
 the fiscal year."

29       9. Throughout the Relevant Period, the Individual Defendants caused the  
 30 Company to issue false and misleading statements that failed to disclose several  
 31 material adverse facts about the Company's business, operations, and prospects.  
 32 Specifically, the Individual Defendants caused the Company to make false and/or

misleading statements and/or fail to disclose: (1) that the Company was willfully infringing patents held by CMU that were material to Marvell's business and revenues; (2) that, as a result, the Company was exposed to very material and significant damages to CMU; (3) that the Company lacked adequate internal controls; and (4) as a result of the above, the Company's SEC filings were materially false and misleading at all relevant times.

10. The Individual Defendants' misconduct has damaged Marvell and its shareholders. Marvell has had a judgment of \$1.54 billion entered against it. Marvell will have to pay future additional damages since the Judgment obligates Marvell to pay an ongoing royalty on infringed chips sold by Marvell of \$0.50 per chip. With respect to ongoing royalties, on May 1, 2014, Marvell and CMU filed a Joint Report with Judge Fischer indicating that Marvell's sales of infringing chips during the period November 3, 2012 through February 1, 2014 was in excess of \$390 million.<sup>2</sup> Thus, Marvell is exposed to ongoing royalty damages of at least \$195 million (as of February 1, 2014) in addition to the Judgment. Marvell has incurred, or will incur, millions of dollars in costs and fees for defending itself in the CMU litigation. Additionally, the Company's goodwill and reputation have been materially undermined and tarnished as a result of the litigation.

## JURISDICTION AND VENUE

11. Jurisdiction is conferred by 28 U.S.C. § 1332. There is complete diversity among the parties and the amount in controversy exceeds the sum or value of \$75,000, exclusive of interest and costs.

12. Venue is proper in this district pursuant to 28 U.S.C. § 1391 because Marvell maintains its principal executive offices in this district, one or more of the Individual Defendants resides in this district, a substantial portion of the

<sup>2</sup> Marvell and CMU disagreed slightly on the exact sales figures. Marvell listed total sales during this time period of \$390,726,473, while CMU listed sales of \$392,029,138.

1 transactions and wrongs complained of herein—including the Individual  
 2 Defendants' primary participation in the wrongful acts—occurred in this district,  
 3 and Individual Defendants have received substantial compensation in this district by  
 4 doing business here and engaging in numerous activities that had an effect in this  
 5 district. Marvell's conduct in infringing patents held by CMU occurred in Santa  
 6 Clara, California.

7 **PARTIES**

8 **I. Plaintiffs**

9 13. Plaintiff Lee Voss currently owns over 600 shares of Marvell common  
 10 stock and has continuously held such shares since at least 2008. Mr. Voss is a  
 11 citizen of Virginia.

12 14. Plaintiff Sebastiano D'Arrigo currently owns 20,000 shares of Marvell  
 13 common stock and has continuously held such stock since at least 2000. Mr.  
 14 D'Arrigo is a subject of a foreign state.

15 15. Plaintiffs James DiBiase and Marie DiBiase are married individuals  
 16 who jointly and currently own 2,825 shares of Marvell common stock and have  
 17 continuously held such shares since at least 2006. Mr. & Mrs. DiBiase are citizens of  
 18 New York.

19 **II. Nominal Defendant**

20 16. Nominal Defendant Marvell is a Bermuda corporation with its  
 21 principal executive offices located at 5488 Marvell Lane, Santa Clara, California  
 22 95054. Marvell's stock is traded on the NASDAQ exchange under the ticker MRVL.  
 23 Marvell is a fabless semiconductor company which designs and develops a wide  
 24 variety of integrated circuit devices. Marvell has no employees located in Bermuda;  
 25 all, or substantially all, of its employees and assets are located in California. Marvell  
 26 is a citizen of California and a citizen of Bermuda.

27 **III. The Individual Defendants**

28 17. Defendant Sehat Sutardja is the co-founder of Marvell and has been a

1 member of Marvell's Board of Directors (the "Board"), the Chairman, and Chief  
 2 Executive Officer ("CEO") of Marvell at all relevant times. Marvell represents that  
 3 Sehat Sutardja is technically sophisticated with respect to Marvell's technology and  
 4 that he "has been awarded more than 260 patents, recognized as the Inventor of the  
 5 Year by the Silicon Valley Intellectual Property Law Association and has been named  
 6 a Fellow of IEEE." Thus, Sutardja is an expert with respect to patents, the patent  
 7 application process, and the consequences for patent infringement. Marvell's  
 8 website states the following with respect to Sutardja:

9                   As co-founder of Marvell Technology Group Ltd., Dr. Sutardja has  
 10 served as Chief Executive Officer since its inception and President from  
 11 inception until July 2013. Dr. Sutardja has also served as Co-Chairman  
 12 of the Board of Directors from inception until 2003 and as Chairman of  
 13 the Board since 2003. In addition, he serves as President, Chief  
 14 Executive Officer, and as a Director of Marvell's U.S. operating  
 15 subsidiary, Marvell Semiconductor, Inc. While remaining deeply  
 involved in the daily challenges of running a global growth company, Dr.  
 Sutardja participates heavily in Marvell's engineering and marketing  
 efforts across analog, video processor, and microprocessor design while  
 offering input across all of the company's other product lines.

16 Before co-founding Marvell, Sutardja had worked at Micro Linear and Integrated  
 17 Information Technology, focusing on chips, digital circuits, and digital signal  
 18 processors. Sutardja holds Master of Science and PhD degrees in Electrical  
 19 Engineering and Computer Science from the University of California at Berkeley. He  
 20 received a Bachelor of Science degree in Electrical Engineering from Iowa State  
 21 University. Upon information and belief, Sutardja is a citizen of California.

22           18. Defendant Juergen Gromer has been a member of the Board since  
 23 October 2007. Gromer serves as Chairman of Marvell's Audit Committee and also  
 24 serves on the Executive Compensation Committee and Nominating and Governance  
 25 Committee. Gromer is the retired President of Tyco Electronics Ltd., an electronics  
 26 company, a position which he held from April 1999 until December 31, 2007. Dr.  
 27 Gromer formerly held senior management positions from 1983 to 1998 at AMP  
 28 Incorporated (acquired by Tyco International in April 1999) including Senior Vice

1 President of Worldwide Sales and Services, President of the Global Automotive  
 2 Division, Vice President of Central and Eastern Europe and General Manager of  
 3 AMP. Gromer received his undergraduate degree and Ph.D. in Physics from the  
 4 University of Stuttgart, Germany. Upon information and belief, Gromer is a citizen  
 5 of Germany.

6       19. Defendant John G. Kassakian has been a member of the Board since  
 7 July 2008. Kassakian is a member of Marvell's Audit Committee and also serves on  
 8 the Executive Compensation Committee and Nominating and Governance  
 9 Committee. Marvell represents that Kassakian, who holds a Ph.D., is an expert in the  
 10 semiconductor field and states the following about him on the Company's website:

11                   Kassakian has been a member of the faculty of Electrical  
 12 Engineering and Computer Science at the Massachusetts Institute of  
 13 Technology ("MIT") since 1973 and has served as Director of the MIT  
 14 Laboratory for Electromagnetic and Electronic Systems from 1991 to  
 15 2009. Dr. Kassakian is the founding President of the IEEE Power  
 16 Electronics Society, a member of the National Academy of Engineering,  
 17 and is the recipient of the IEEE Centennial Medal, the IEEE William E.  
 18 Newell Award, the IEEE Power Electronics Society's Distinguished  
 19 Service Award and the IEEE Millennium Medal. Dr. Kassakian's  
 20 expertise in the semiconductor field and academic experience related to  
 21 the technology sector makes Dr. Kassakian a valuable contributor to our  
 22 board of directors.

23                   Upon information and belief, Kassakian is a citizen of Massachusetts.

24       20. Defendant Pantas Sutardja is the brother of Defendant Sehat Sutardja,  
 25 and is also one of the co-founders of Marvell. During the Relevant Period, Pantas  
 26 Sutardja was the director, Vice President, Chief Technology Officer, and Chief R&D  
 27 Officer at Marvell. Collectively, Pantas Sutardja, his brother, and his brother's wife  
 28 (Weili Dai, who serves as Marvell's Vice President and General Manager of  
 Communications and Consumer Business) own and control approximately 19% of  
 Marvell's stock. Upon information and belief, Pantas Sutardja is a citizen of  
 California.

29       21. Defendant Arturo Krueger is a member of the Board and has been a

1 director at all relevant times and since August 2005. Mr. Krueger is the Chair of the  
 2 Board's Nominating and Governance Committee and is also a member of the Board's  
 3 Audit Committee and Executive Compensation Committee. Mr. Krueger holds an  
 4 MS in Electrical Engineering from the Institute of Technology in Switzerland and  
 5 has studied Advanced Computer Science at the University of Minnesota. Marvell's  
 6 website states the following about Mr. Krueger:

7       Mr. Krueger has more than 40 years of experience in the  
 8 international semiconductor industry and acquired a wealth of  
 9 experience in complex systems architecture, semiconductor design and  
 10 development, operations, and international marketing, as well as general  
 11 management of a large company. Since his retirement in February 2001,  
 12 Mr. Krueger has been a consultant to automobile manufacturers and to  
 13 semiconductor companies serving the automotive and  
 14 telecommunication markets and is serving on several advisory boards.  
 15 Prior to his retirement in 2001, Mr. Krueger had joined Motorola in 1996  
 16 as a systems engineer and last served as Corporate Vice President and  
 17 General Manager of Motorola Corporation's Semiconductor Products  
 18 Sector for Europe, Middle East and Africa from January 1998 until  
 19 February 2001. During his time at Motorola, Mr. Krueger served as the  
 20 director of the Advanced Architectural and Design Automation Lab. Mr.  
 21 Krueger brings a deep understanding of the modern semiconductor  
 22 industry, the complex world of microelectronic systems design and  
 23 architectures, and the financial aspects of running a large company.

24 Krueger currently also serves on the board of QuickLogic Corporation, another  
 25 semiconductor company. Upon information and belief, Krueger is a citizen of  
 26 California.

27       22. Defendant Randhir Thakur was, at all relevant times, a member of the  
 28 Board. He is also a member of Marvell's Nominating and Governance Committee,  
 29 the Board's Audit Committee, and the Executive Compensation Committee.  
 30 Marvell's website states the following concerning Dr. Thakur:

31       Dr. Randhir Thakur is executive vice president and general  
 32 manager of the Silicon Systems Group at Applied Materials, Inc., which  
 33 comprises the entire portfolio of semiconductor manufacturing systems  
 34 at Applied Materials. In this role, Dr. Thakur is responsible for  
 35 strengthening Applied Materials' leadership in its core wafer fabrication  
 36 equipment markets. Since rejoining Applied Materials in May 2008, Dr.  
 37 Thakur has served in various executive positions, including senior vice

1 president and general manager of the Display and Thin Film Solar group,  
 2 where he led the business offering manufacturing systems for flat panel  
 3 displays and Applied Materials' thin film solar products. From 2005 to  
 4 May 2008, Dr. Thakur worked at SanDisk Corporation, a supplier of  
 5 innovative flash memory data storage products, where he served as  
 6 executive vice president of Technology and Fab Operations and head of  
 7 worldwide operations. From 2000 to 2005, Dr. Thakur held a series of  
 8 progressively advancing executive roles within various semiconductor  
 9 product groups at Applied Materials, including group vice president and  
 10 general manager of Front End Products. Prior to joining Applied  
 11 Materials in 2000, Dr. Thakur served as chief technology officer and  
 12 general manager at Steag Electronic Systems, and vice president of  
 13 Research Development and Technology at AG Associates, and held  
 14 various technical leadership positions at Micron Technology. Dr. Thakur  
 15 brings a wealth of experience in the semiconductor and consumer  
 16 electronics industry, while helping to grow new markets and new  
 17 products. We believe with his past and current experience in managing a  
 18 large customer-focused and innovation-driven organization and various  
 19 aspects of operations management and manufacturing, Dr. Thakur will  
 20 be a valuable new addition to our board of directors.

21 Dr. Thakur holds a BS with honors in Electronics and Telecommunications  
 22 Engineering from the National Institute of Technology, Kurukshetra, India, an MS  
 23 in Electrical Engineering from the University of Saskatchewan, Canada and a Ph.D.  
 24 in Electrical Engineering from the University of Oklahoma. Dr. Thakur holds close  
 25 to 300 patents and has published more than 200 papers. Upon information and  
 26 belief, Thakur is a citizen of California.

27       23. Defendant Weili Dai is one of Marvell's co-founders and served as Vice  
 28 President, Corporate Secretary, and a director of Marvell since the company was  
 1 established in 1995. Since 1999, Ms. Dai has served as Executive Vice President and  
 2 General Manager of the Communications Business Group and has been responsible  
 3 for managing all of the Company's communications product lines. Ms. Dai has also  
 4 served as Executive Vice President and a director of Marvell Semiconductor, Inc.  
 5 since its inception. In 2006, Ms. Dai was named Chief Operating Officer of Marvell.  
 6 Effective July 14, 2013, Ms. Dai was named President of Marvell. Prior to founding  
 7 Marvell, Ms. Dai was involved in software development and project management at  
 8 Canon Research Center America, Inc. Ms. Dai holds a Bachelor of Science degree in

1 Computer Science from the University of California at Berkeley. Upon information  
 2 and belief, Dai is a citizen of California.

3       24. The Defendants identified in paragraphs 17 through 23 are collectively  
 4 referred to herein as the “Individual Defendants.”

5       25. The true names and capacities, whether individual, corporate,  
 6 associate, or otherwise, of Defendants named in this action as Does 1-20, inclusive,  
 7 are unknown to Plaintiffs, who, therefore, sue these defendants by such fictitious  
 8 names. Plaintiffs will amend this complaint to show their true name(s) and  
 9 capacities when they have been ascertained. Plaintiffs are informed and believe, and  
 10 on that basis allege, that each of these fictitiously-named defendants is responsible  
 11 in some manner for the occurrences herein alleged, and that the nominal  
 12 defendant’s injuries as alleged in this complaint were proximately caused by the  
 13 conduct of these fictitiously-named defendants.

14       26. Because of their high-level positions with Marvell, each Individual  
 15 Defendant directed the business of Marvell and had responsibility for, control of,  
 16 and/or knowledge of the content and timing of all of Marvell’s press releases, public  
 17 filings, and other public statements, including those described herein. Further, each  
 18 Individual Defendant’s position gave him or her access to non-public information  
 19 about Marvell’s business, finances, products, markets, and present and future  
 20 business prospects. Each Individual Defendant also knew that the unfavorable facts  
 21 specified herein had not been disclosed to the investing public and that the positive  
 22 representations that were being made were both false and misleading.

23       27. Plaintiffs are informed and believe, and on that basis allege, that  
 24 during the Relevant Period, each of the defendants was the agent, principal,  
 25 representative, and/or employee of each of the other defendants, and, in doing the  
 26 things mentioned herein, was acting within the scope of said agency, representation,  
 27 and/or employment with permission of each co-defendant.

## **CONSPIRACY, AIDING AND ABETTING, AND CONCERTED ACTION**

28. In committing the wrongful acts alleged herein, the Individual Defendants have pursued, or joined in the pursuit of, a common course of conduct, and have acted in concert with and conspired with one another in furtherance of their common plan or design. In addition to the wrongful conduct alleged in this complaint as giving rise to primary liability, the Individual Defendants further aided and abetted and/or assisted each other in breaching their respective duties.

29. During all times relevant hereto, the Individual Defendants collectively and individually initiated a course of conduct that was designed to and did: (i) conceal the fact that the Company was willfully infringing patents held by CMU; (ii) maintain the Individual Defendants' executive and directorial positions at Marvell and the profits, power, and prestige that the Individual Defendants enjoyed as a result of these positions; and (iii) deceive the investing public, including shareholders of Marvell, regarding the Individual Defendants' management of Marvell's operations, the Company's financial health and stability, and future business prospects, specifically related to the Company's chips which infringed the process patents held by CMU. In furtherance of this plan, conspiracy, and course of conduct, the Individual Defendants collectively and individually took the actions set forth herein.

30. The Individual Defendants engaged in a conspiracy, common enterprise, and/or common course of conduct commencing by at least 2003 and continuing thereafter. During this time, the Individual Defendants caused the Company to conceal the true fact that Marvell was willfully infringing patents held by CMU that were material to Marvell's business.

31. The Individual Defendants accomplished their conspiracy, common enterprise, and/or common course of conduct by causing the Company to purposefully, recklessly or negligently refuse to license the CMU patents after CMU

1 put Marvell on notice of its patents beginning in 2003.<sup>3</sup> After intentionally refusing  
 2 to license the CMU patents, Marvell then willfully infringed CMU's patents by  
 3 incorporating CMU's process patents into the technology for its products. Because  
 4 the actions described herein occurred under the authority of the Board, which to a  
 5 certain extent relies on the representations of the Company's officers, each of the  
 6 Individual Defendants was a direct, necessary and substantial participant in the  
 7 conspiracy, common enterprise, and/or common course of conduct complained of  
 8 herein.

9       32. Each of the Individual Defendants aided and abetted and rendered  
 10 substantial assistance in the wrongs complained of herein. In taking such actions to  
 11 substantially assist the commission of the wrongdoing complained of herein, each  
 12 Individual Defendant acted with knowledge of the primary wrongdoing,  
 13 substantially assisted the accomplishment of that wrongdoing, and was aware of his  
 14 or her overall contribution to and furtherance of the wrongdoing.

#### 15                   **DUTIES OF THE INDIVIDUAL DEFENDANTS**

16       33. By reason of their positions as officers, directors and/or fiduciaries of  
 17 Marvell, and because of their ability to control the business and corporate affairs of  
 18 Marvell, the Individual Defendants owed the Company and its shareholders  
 19 fiduciary obligations of trust, loyalty, good faith, and due care, and were, and are,  
 20 required to use their utmost ability to control and manage Marvell in a fair, just,  
 21 honest, and equitable manner. The Individual Defendants were, and are, required to  
 22 act in furtherance of the best interests of Marvell and its shareholders so as to  
 23 benefit all shareholders equally, not in furtherance of their personal interest or  
 24 benefit.

25       34. Each director and officer of the Company owes to Marvell and its

---

26       3 As alleged in more detail herein, Defendant Sehat Sutardja testified on  
 27 December 11, 2012 at CMU's patent infringement trial that he was aware of CMU's  
 28 patents but declined to license CMU's technology because Marvell was "not interested  
 in using [CMU's] technology in our chip."

1 shareholders the fiduciary duty to exercise good faith and diligence in the  
 2 administration of the affairs of the Company and in the use and preservation of its  
 3 property and assets, and the highest obligations of fair dealing. In addition, as  
 4 officers and/or directors of a publicly held company, the Individual Defendants had  
 5 a duty to promptly disseminate accurate and truthful information with regard to the  
 6 Company's technology, patents, revenue, margins, operations, performance,  
 7 management, projections, and forecasts so that the market price of the Company's  
 8 stock would be based on truthful and accurate information.

9       35. The Individual Defendants, because of their positions of control and  
 10 authority as directors and/or officers of Marvell, were able to, and did, directly  
 11 and/or indirectly, exercise control over the wrongful acts complained of herein, as  
 12 well as the contents of the various public statements issued by the Company.  
 13 Because of their advisory, executive, managerial and directorial positions with  
 14 Marvell, each of the Individual Defendants had access to adverse non-public  
 15 information about the financial condition, operations, and improper representations  
 16 of Marvell.

17       36. At all times relevant hereto, each of the Individual Defendants was the  
 18 agent of each of the other Individual Defendants and of Marvell, and was at all times  
 19 acting within the course and scope of such agency.

20       37. To discharge their duties, the officers and directors of Marvell were  
 21 required to exercise reasonable and prudent supervision over the management,  
 22 policies, practices and controls of the financial affairs of the Company. By virtue of  
 23 such duties, the officers and directors of Marvell were required to, among other  
 24 things:

- 25           (a) refrain from acting upon material inside corporate information to benefit  
 26           themselves;
- 27           (b) ensure that Marvell did not infringe patents held by others;
- 28           (c) ensure that the Company complied with its legal obligations and  
 requirements, including acting only within the scope of its legal authority

1 and disseminating truthful and accurate statements to the SEC and the  
 2 investing public;

3 (d) conduct the affairs of the Company in an efficient, business-like manner  
 4 so as to make it possible to provide the highest quality performance of its  
 5 business, to avoid wasting the Company's assets, and to maximize the  
 6 value of the Company's stock;

7 (e) properly and accurately guide investors and analysts as to the true  
 8 financial condition of the Company at any given time, including making  
 9 accurate statements about the Company's technology, patents, financial  
 10 results and prospects, and ensuring that the Company maintained an  
 11 adequate system of internal controls such that the Company's financial  
 12 reporting would be true and accurate at all times;

13 (f) remain informed as to how Marvell conducted its operations, and, upon  
 14 receipt of notice or information of patent violations or imprudent or  
 15 unsound conditions or practices, make reasonable inquiry in connection  
 16 therewith, and take steps to correct such conditions or practices and  
 17 make such disclosures as necessary to comply with patent laws and  
 18 federal and state securities laws; and

19 (g) ensure that the Company was operated in a diligent, honest and prudent  
 20 manner in compliance with all applicable federal, state and local laws,  
 21 rules and regulations.

22 38. Each Individual Defendant, by virtue of his or her position as a director  
 23 and/or officer, owed to the Company and to its shareholders the fiduciary duties of  
 24 loyalty, candor, good faith and the exercise of due care and diligence in the  
 25 management and administration of the affairs of the Company, as well as in the use  
 26 and preservation of its property and assets. The conduct of the Individual  
 27 Defendants complained of herein involves a knowing and culpable violation of their  
 28 obligations as directors and officers of Marvell, the absence of good faith on their  
 29 part, a breach of their duty of candor, and a reckless disregard for their duties to the  
 Company and its shareholders that the Individual Defendants were aware or should  
 have been aware posed a risk of serious injury to the Company.

30 39. According to the Company, the primary role of the Board at the  
 31 Company is to oversee management by monitoring the performance of the CEO and  
 32 other senior executives and to ensure that the best interests of shareholders are  
 33 being served. To satisfy this responsibility, the Board is expected to take a proactive  
 34 approach to its duties and function as active monitors of corporate executives.

1 Board members are required to provide oversight in the formulation of the long-  
 2 term strategic, financial, and organizational goals of the Company and of the plans  
 3 designed to achieve those goals. In addition, the Board oversees and reviews the  
 4 standards and policies designed and implemented by senior management to ensure  
 5 that the employees and other constituents of the Company are committed to  
 6 achieving corporate objectives through the highest standards of responsible conduct  
 7 and ethical behavior and full compliance with legal requirements.

8       40. In addition, the Audit Committee members owed specific duties  
 9 because of the added responsibilities of this Board subcommittee.

10      41. Each member of the Audit Committee is required to be, and in fact is  
 11 represented by the Individual Defendants as, financially literate and having the  
 12 requisite financial sophistication as required by the applicable listing standards of  
 13 the Nasdaq Stock Market.

14      42. The purpose of the Audit Committee, pursuant to its charter, is to  
 15 “assist the Board of Directors (the “Board”) of Marvell Technology Group Ltd. (the  
 16 “Company”) in fulfilling its responsibilities for oversight of the quality and integrity  
 17 of the accounting, auditing and reporting practices of the Company. The purpose of  
 18 the Committee is to oversee management’s conduct of the Company’s accounting  
 19 and financial reporting processes, including the review of financial reports and other  
 20 financial information provided by the Company to its shareholders; reviewing the  
 21 Company’s systems of internal accounting, financial and disclosure controls and the  
 22 annual independent audit of the Company’s financial statements; and appointing,  
 23 retaining and overseeing the performance of independent accountants.”

24      43. The Audit Committee Charter states that the committee shall be  
 25 responsible for the following tasks:

26      The following functions shall be the **common recurring activities of**  
 27 **the Committee** in carrying out its oversight function. These functions  
 28 are set forth as a guide with the understanding that the Committee may  
 diverge from this guide as appropriate given the circumstances:

- 1        •     Review and discuss the Company's annual audited financial  
 2        statements and quarterly financial statements with management and the  
 3        external auditors, including the Company's disclosures under the section  
 4        entitled "Management's Discussion and Analysis of Financial Condition  
 5        and Results of Operations" in the Company's reports filed with the SEC  
 6        and, with respect to the annual financial statements, the appropriateness  
 7        and quality of accounting and auditing principles and practices as well as  
 8        the adequacy of internal controls that could significantly affect the  
 9        Company's financial statements;
- 10       •     Review and consider with the external auditors the matters  
 11       required to be discussed by Statement of Auditing Standards ("SAS") No.  
 12       61 and No. 90 and all other applicable standards and rules, as all may be  
 13       amended from time to time, relating to the conduct of the audit, other  
 14       significant financial reporting issues and judgments made by  
 15       management in connection with the preparation of the Company's  
 16       financial statements, and any other matters communicated to the  
 17       Committee by the external auditors;
- 18       •     Review disclosures made to the Committee by the Company's chief  
 19       executive officer and chief financial officer during their certification  
 20       process for Forms 10-K and 10-Q about any significant deficiencies in the  
 21       design or operation of internal controls or material weaknesses therein  
 22       and any fraud involving management or other employees who have a  
 23       significant role in the Company's internal controls over financial  
 24       reporting; and
- 25       •     Review the independence and performance of the external  
 26       auditors.

18               With respect to the independence of the independent auditors, the  
 19       Committee shall:

- 20       •     Request from the external auditors annually, a formal written  
 21       statement delineating all relationships between the auditor and the  
 22       Company required by the Public Company Accounting Oversight Board;
- 23       •     Discuss with the external auditors any such disclosed  
 24       relationships and their impact on the outside auditor's independence;  
 25       and
- 26       •     Recommend that the Board take appropriate action to oversee the  
 27       independence of the external auditors.

28       44.       Marvell's Executive Compensation Committee Charter states the  
 following with respect to the purpose of the Committee and the duties of its  
 members:

The purpose of the Executive Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Marvell Technology Group Ltd. (the “Company”) is to:

1. carry out the Board's overall responsibility relating to compensation of the Company's executive officers, as designated from time to time by the Company for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act");
2. assist the Board in establishing the appropriate incentive compensation and equity-based plans for the Company's executive officers and to administer such plans;
3. produce an annual report on executive officer compensation for inclusion in the Company's annual proxy statement or annual report on Form 10-K; and
4. perform such other duties and responsibilities enumerated in and consistent with this Charter.
45. Marvell states that the following shall be the ***common recurring***

***duties of the Committee*** in carrying out its oversight functions:

The duties and responsibilities are set forth below as a guide to the Committee with the understanding that the Committee may alter or supplement them as appropriate under the circumstances to the extent permitted by applicable law, regulation or Nasdaq Rule.

The Committee shall:

1. Review and approve corporate goals and objectives relevant to the compensation of the executive officers.
2. Evaluate the performance of the executive officers in light of such goals and objectives at least annually and communicate the results to such officers and the Board.
3. Based on the evaluation in 2. above, establish and approve annually for the Chief Executive Officer and such other executive officers, the compensation levels for those persons including, as applicable, (a) base salary, (b) bonus, (c) long-term incentive and equity compensation, and (d) any other compensation, perquisites, and special or supplemental benefits. In evaluating and determining compensation for the Chief Executive Officer and such other executive officers, the Committee shall consider the results of the most recent shareholder advisory vote on executive compensation required by Section 14A of the Exchange Act.
4. In determining the long-term incentive component of such executive officers' compensation, consider, among other items, the Company's performance and relative shareholder return, the value of similar incentive awards to chief executive officers and other executive officers at

1 comparable companies, and the compensation provided to each such  
 2 executive officer in the past.

3

5. Establish and modify the terms and conditions of employment of the  
 6 executive officers, by contract or otherwise.

7. Determine the provisions of any contracts for the executive officers that  
 8 will govern the situation in which severance payments will be due upon  
 9 change in control situations.

10. Administer executive officer compensation in accordance with the terms  
 11 of any applicable Company compensation plans expressly drawn or  
 12 adopted for such positions.

13. On a regular basis, but not less than annually, the Committee shall report  
 14 to the Board on the Chief Executive Officer's performance and  
 15 compensation and the compensation of the other executive officers.  
 16 Deliberations and voting with respect to the Chief Executive Officer's  
 17 compensation shall be conducted in the absence of the Chief Executive  
 18 Officer.

19. Review the Company's incentive compensation and other equity-based  
 20 plans and practices and recommend changes in such plans and practices  
 21 to the Board.

22. Review the Company's benefit plans (including but not limited to 401(k),  
 23 employee stock purchase plan and bonus plans).

24. Administer the Company's equity incentive plans. In its administration of  
 25 the plans, the Committee may, pursuant to authority delegated by the  
 26 Board, (i) grant share options or share purchase rights to individuals  
 27 eligible for such grants and in accordance with procedures and guidelines  
 28 as may be established by the Board, and (ii) amend such share options or  
 29 share purchase rights. The Committee shall also make recommendations  
 30 to the Board with respect to amendments to the plans and changes in the  
 31 number of shares reserved for issuance thereunder.

32. Prepare the annual report on executive officer compensation that  
 33 complies with applicable law, including the Exchange Act, for inclusion  
 34 in the Company's annual proxy statement. Annually review and discuss  
 35 the Compensation Discussion and Analysis (the "CD&A") and related  
 36 executive compensation information with management, and, if  
 37 appropriate, recommend to the Board that the CD&A and related  
 38 executive compensation information be included in the annual proxy  
 39 statement or annual report.

40. Perform an annual performance evaluation of the Committee.

41. To review and recommend to the Board for approval the frequency with  
 42 which the Company will conduct shareholder advisory votes on executive  
 43 compensation ("Say on Pay Vote"), taking into account the results of the  
 44 most recent shareholder advisory vote on frequency of Say on Pay Votes  
 45 required by Section 14A of the Exchange Act, and review and approve the  
 46 proposals regarding the Say on Pay Vote and the frequency of the Say on  
 47 Pay Vote to be included in the Company's proxy statement.

1        15. Perform such other activities and functions related to executive officer  
 2        compensation as assigned by law or the Company's Memorandum of  
 3        Association or Bye-Laws, or as may be assigned from time to time by the  
 4        Board.

5        The Committee shall ensure that compensation programs are designed to  
 6        encourage high performance, promote accountability and assure that employee  
 7        interests are aligned with the interests of the Company's shareholders.

8        46. Marvell's Nominating and Governance Committee has the following  
 9        duties, according to its Charter:

10       The following shall be the **common recurring duties of the Committee** in carrying out its oversight functions. The duties and responsibilities are set forth below as a guide to the Committee with the understanding that the Committee may alter or supplement them as appropriate under the circumstances to the extent permitted by applicable law, regulation or Nasdaq Rule.

11       The Committee shall:

12       1. Review and report to the Board on a periodic basis with respect to matters of corporate governance (which is defined for this purpose as the relationships of the Board, the shareholders and management in determining the direction and performance of the Company).

13       2. Annually review and assess the effectiveness of the Board's Corporate Guidelines and other policies essential to the sound and proper management of the Company's business.

14       3. Be responsible for overseeing the Board performance evaluation process including conducting surveys of director observations, suggestions and preferences.

15       4. From time to time, conduct studies of the size and composition of the Board and its committees, and periodically review with the Board and assess the criteria and requirements for Board and committee membership including without limitation, stock ownership requirements.

16       5. Assist in the recruiting of directors and recommend procedures for the nomination process, and screen and recommend candidates for election to the Board and to serve as members of committees, which may include new directors for election by the shareholders and otherwise by appointment to fill vacancies and newly created directorships.

17       6. Annually review and evaluate the nomination for re-election of current directors.

18       7. Consider shareholder nominees for election to the Board.

- 1        8. In connection with the review and evaluation of potential directors,  
2            periodically review the Company's Policies And Procedures For  
3            Evaluation of Director Candidates.
- 4        9. Oversee education and training programs for Board members.
- 5        10. Periodically review with the Chairman of the Board and the Chief  
6            Executive Officer Company leadership roles, leadership development  
7            programs, and succession plans relating to positions held by executive  
8            officers, and make recommendations to the Board with respect to  
9            selection of individuals to occupy those positions.
- 10       11. Periodically review director compensation for service on the Board and  
11            recommend any changes in director compensation to the Board.
- 12       12. Be responsible for related party transactions as follows:
  - 13       (a) The Committee shall review and approve policies and procedures  
14            with respect to proposed transactions between the Company and  
15            related parties; and
  - 16       (b) The Committee shall review and approve (including by  
17            ratification, if applicable) all such related party transactions that  
18            would require disclosure pursuant to the rules of the U.S.  
19            Securities and Exchange Commission, and other related party  
20            transactions required by Company policy to be reviewed and  
21            approved.
- 22       13. Regularly report on Committee activities to the Board.

23       In performing its duties hereunder, the Committee will endeavor  
24            to comply with applicable legal requirements, including but not limited  
25            to the Sarbanes-Oxley Act of 2002, federal securities laws and the  
26            Nasdaq Rules.

## 27            **SUBSTANTIVE ALLEGATIONS**

### 28       **I. Marvell Was Founded by the Sutardja Brothers and Dai**

29       47. Marvell was founded in 1995 by brothers Sehat and Pantas Sutardja  
30            and Sehat's wife, Weili Dai. It has been reported that Defendant Dai picked the  
31            name for the company and based it on a diminution of the word "marvelous."

32       48. Marvell is a fabless semiconductor company which designs and  
33            develops a wide variety of integrated circuit devices. The Company states in its  
34            annual reports that:

[Marvell] is a fabless semiconductor provider of high-performance application-specific standard products (ASSPs). Our core strength of expertise is the development of complex System-on-a-Chip (SoC) devices leveraging our extensive portfolio of intellectual property (IP) in the areas of analog, mixed-signal, digital signal processing and embedded ARM-based microprocessor integrated circuits. Our product portfolio includes devices for data storage, enterprise-class Ethernet data switching, Ethernet physical-layer transceivers, handheld cellular, Ethernet-based wireless networking, personal area networking, Ethernet-based PC connectivity, control plane communications controllers, video-image processing and power management solutions. Our products serve diverse applications used in carrier, metropolitan, enterprise and PC-client data communications and storage systems. Additionally, we serve the market for the convergence of voice, video and data applications in the consumer electronics market.<sup>4</sup>

49. Marvell's major customers include Fujitsu, Hitachi, IBM, Maxtor, Samsung, Seagate Technology, Toshiba, and Western Digital. Before such customers order semiconductor chips from Marvell, they engage in a lengthy evaluation and implementation process, all of which occurs at Marvell's Santa Clara, California headquarters.

## II. The Once and Future King and Queen of Marvell: Defendants Sutardja and Dai's History of Self-Dealing and Dishonesty, Blessed and Approved by a Supine Board

50. This action involves the defendants' dishonesty and lack of candor with respect to willful infringement of patents held by CMU. Defendants' wrongdoing in this regard has caused Marvell to be damaged in excess of \$1.54 billion, while the Individual Defendants named herein have benefitted themselves financially by tens of millions of dollars.

51. A review of the Individual Defendants' past wrongdoing at Marvell is illuminating to demonstrate the Individual Defendants' pattern and practice of breaching their fiduciary duties in a willful and dishonest manner to benefit themselves financially at the expense of Marvell and its public, minority shareholders. Defendants' past and current conduct constitutes a fraud on the minority shareholders, as that term is understood under Bermuda law.

---

<sup>4</sup> See Marvell's 2008 Annual Report on Form 10-K at 4.

1        52. In 2006, the same year Defendant Dai was named Chief Operating  
 2 Officer (“COO”), Marvell received a letter of informal inquiry from the Securities and  
 3 Exchange Commission (SEC) requesting certain documents relating to the  
 4 company’s stock option grants and practices.

5        53. At Marvell, the same day the SEC probe was announced, the U.S.  
 6 Attorney’s office in San Francisco served the company with a grand jury subpoena  
 7 for stock options records. Ten months later, on May 7, 2007, a two-person Special  
 8 Committee appointed by Marvell’s Board to investigate the Company’s practices  
 9 concluded that Marvell had backdated options and that Sutardja had participated in  
 10 the backdating in some cases.

11        54. In a typical backdating scheme, directors or executives granted options  
 12 at the then current stock price. Later, they cherry-picked a time from the past when  
 13 the price was lower, calling that the grant date, to boost the value of the shares.  
 14 Backdating violates federal securities laws if companies fail to account for options  
 15 paid to employees, as Marvell failed to do. On May 7, 2007, Marvell said it would  
 16 restate its financial results by as much as \$350 million. The ultimate amount of the  
 17 restatement was \$327 million.

18        55. Backdating is a bald-faced lie, represents *ultra vires* conduct, and  
 19 constitutes a breach of the duty of candor.

20        56. “The Special Committee found a systemic failure of internal controls,”  
 21 Marvell said in an SEC filing at the time. Marvell stock, which had climbed to a  
 22 split-adjusted record \$35.32 on January 27, 2006, plunged 53% to \$16.37 on May  
 23 21, 2007, destroying more than \$10 billion in market value.

24        57. Marvell’s Special Committee, after concluding that Marvell’s executives  
 25 and directors had backdated options, recommended several remedial actions,  
 26 including stripping Defendant Sehat Sutardja (the CEO of Marvell) of his Chairman  
 27 duties and terminating the services of Ms. Dai, who was said to bear a certain  
 28 amount “of responsibility for these deficiencies.” The Board ignored these decisions,

1 choosing instead to “demote” Ms. Dai and to appoint an independent lead director  
 2 (temporarily) instead of reducing the CEO’s control of the Board.

3       58. The fact that the husband/wife duo of Defendants Sehat Sutardja and  
 4 Weili Dai ignored governance changes recommended by the allegedly independent  
 5 Board members, despite their highly unethical and unlawful behavior, demonstrates  
 6 that Sutardja and Dai exercise unfettered control of Marvell’s operations. Such  
 7 domination and control of Marvell’s Board by Sutardja and Dai persists to this day.

8       59. Both shareholder lawsuits and news articles at the time noted that  
 9 from 2001 to 2006, Defendants Sehat Sutardja and Ms. Dai (along with fellow  
 10 officers and directors) received **more than \$760 million from the sale of 36**  
 11 **million Marvell shares, most of which were backdated.**<sup>5</sup> As a Bloomberg  
 12 article noted,

13           In a setup that differs from that at most companies, Sutardja and  
 14 Dai were the sole members of the committee that doled out options. It’s  
 15 unusual to have a married couple occupying the senior executive  
 16 positions in a company, let alone allow them to be in charge of handing  
 17 out stock-based compensation.<sup>6</sup>

18       60. Defendant Dai has been reported to order Italian designer furniture  
 19 from Gianni Versace for Marvell’s lobby, and for herself a red Ferrari F430 with a  
 20 custom license plate reading “Marvell.”

21       61. In response to the enormous self-dealing by defendants with respect to  
 22 backdating of stock options at Marvell, shareholders filed a shareholder derivative  
 23 action in this Court on November 1, 2006. On March 20, 2009, the case was settled  
 24 and a Stipulation of Settlement was filed with the Court. The defendants paid  
 25 \$54,994,726 to settle the case, plus additional corporate governance changes.  
 26 Defendants in that case included some of the defendants named herein, including  
 27 Sehat and Pantas Sutardja, Weili Dai, and Arturo Krueger. Defendant Gromer filed

---

28           <sup>5</sup> See, e.g., “Billionaires from Jakarta, Shanghai Undermined by Options,”  
 29 BLOOMBERG, May 21, 2007.

28           <sup>6</sup> *Id.*

1 a declaration in support of the settlement, stating that he and Defendant Kassakian  
 2 had approved the settlement.

3       62.   Similar wrongdoing involving backdating of stock options at Marvell,  
 4 and lying to shareholders about it, gave rise to a shareholder class action lawsuit,  
 5 also filed in this Court. Marvell was damaged in that case, which settled for \$72  
 6 million. Judge Whyte entered final judgment on November 13, 2009.

7       63.   Defendant Dai also entered into a settlement with the SEC in which she  
 8 consented to a permanent injunction against any future violations of various  
 9 provisions of the federal securities laws, agreed not to serve as a director or officer of  
 10 a public company for a period of five years, and paid a civil penalty of \$500,000.  
 11 According to the WALL STREET JOURNAL, the SEC said the size of the fines “partly  
 12 reflect that the company didn’t follow the recommendation to fire her. According to  
 13 the SEC’s complaint, Ms. Dai didn’t cooperate with the agency’s investigators and  
 14 invoked her Fifth Amendment right against self-incrimination when asked  
 15 ‘substantive questions’ by SEC staff.”

16       64.   Despite the settlement and her five-year ban on serving as an executive  
 17 officer, Defendant Dai continued to be generously compensated. Immediately after  
 18 her “resignation” in 2007, she received an enormous stock option grant of 6,888,798  
 19 shares. In 2008, she again received a second outsized grant of 7,387,067 shares. In  
 20 2007 and 2008, she received total compensation from Marvell of 7,380,600 and  
 21 7,672,111, respectively.

22       65.   In 2012, Dai received the following compensation package approved by  
 23 the company’s Audit Committee and Executive Compensation Committee:

- 24       1.    a \$400,000 bonus;
- 25       2.    an increase in her annual base salary to \$510,000 (from \$500,000);
- 26       3.    a bonus participation target for Ms. Dai equal to 80% of her base pay;
- 27       4.    a mega-grant of 800,000 options with service-based vesting; and
- 28       5.    a grant of 80,000 restricted stock units with service-based vesting.

29       66.   Altogether, Defendant Dai received compensation of approximately \$6

1 million in 2012, an amount that makes her the second highest paid executive officer  
 2 at Marvell, if she were allowed to be called an “executive.” This represented self-  
 3 dealing conduct countenanced and approved by the Compensation Committee  
 4 (Defendants Gromer, Kassakian, Thakur and Krueger) because Dai’s compensation  
 5 was commensurate with that of an executive officer during the time when she was  
 6 banned under her settlement with the SEC from serving as an executive officer of  
 7 Marvell.

8       67.    Unsurprisingly, as soon as Dai’s five-year ban from serving as an  
 9 executive officer of Marvell expired, the Board promptly named Dai President of the  
 10 Company, effective July 14, 2013. The king and queen were back on their thrones.

11       68.    As part of the stock option backdating scandal at Marvell, the  
 12 Company’s own General Counsel alleged in a whistleblower lawsuit that both  
 13 Defendants Sehat Sutardja and Arturo Krueger pressured him to lie. *See Matthew*  
 14 *Gloss v. Marvell Semiconductor, Inc. and Marvell Technology Group, Ltd.*, Case  
 15 No. 2009-SOX-00011 (U.S. Dept. of Labor, Office of Administrative Law Judges,  
 16 San Francisco, Cal.). In declarations submitted under penalty of perjury, Marvell’s  
 17 former General Counsel Matthew Gloss stated that on the evening of October 25,  
 18 2006, the day before he was scheduled to have his third interview with the Special  
 19 Committee, which had been appointed to investigate the stock option backdating at  
 20 Marvell, Defendant Sehat Sutardja called him at his home in an apparent effort to  
 21 influence his testimony. Gloss Decl. ¶ 3. CEO Sutardja also indicated that he could  
 22 not attest to the accuracy of certain records from Stock Options Committee meetings  
 23 with COO Dai. *Id.* Gloss also stated in his sworn declaration that, on October 26,  
 24 2006, he mentioned the phone call with CEO Sutardja during his interview with  
 25 Special Committee’s counsel Matthew Jacobs. *Id.* Gloss alleges that following the  
 26 interview, Defendant Krueger reprimanded him for disclosing the phone call with  
 27 CEO Sutardja to Jacobs. Gloss Decl. ¶ 4. Gloss further stated that Krueger  
 28 suggested that he should have lied about the nature of the phone call with CEO

1 Sutardja. *Id.*

2 69. In his declaration, Gloss further stated that he reported both the  
 3 Sutardja phone call and the Krueger conversation to Marvell's Chief Financial  
 4 Officer ("CFO") George Hervey and Vice President of World Wide Human Resources  
 5 Michelle Oakes in early November 2006. Gloss Decl. ¶ 5. He also stated he  
 6 discussed the matter with Doug King, the Chair of the Company's Audit Committee  
 7 in mid-January, 2007. Gloss Decl. ¶ 7. On February 7, 2007, Gloss met with King a  
 8 second time, providing him with a letter questioning Krueger's independence on the  
 9 Special Committee. Gloss expressed similar concerns in a document he submitted to  
 10 the SEC the following day. Gloss Decl. ¶ 8.

11 70. Gloss's declaration further stated that Gloss reiterated his concerns  
 12 about the independence of the Special Committee during his final interview with  
 13 Jacobs on February 13, 2007. Gloss Decl. ¶ 9. In response to Gloss's allegations,  
 14 Marvell asked King to conduct an investigation. King hired retired Federal Judge  
 15 Abraham Sofaer to assist with the investigation. Judge Sofaer, in turn, hired outside  
 16 counsel to aid him in his task. *Id.*

17 71. As a result of Gloss's allegations, Marvell delayed the Special  
 18 Committee's investigation. Gloss stated that, as a result of his complaints, his  
 19 responsibilities as General Counsel were curtailed in November 2006 and  
 20 transferred to a junior attorney. Gloss Decl. ¶ 6. He further stated in his declaration  
 21 that, on March 26, 2007, he was terminated without explanation and barred from  
 22 his office. Gloss Decl. ¶ 6.

23 72. Gloss filed a whistleblower lawsuit under the Sarbanes-Oxley Act,  
 24 claiming that his termination was in retaliation for his reports of unlawful conduct  
 25 by Marvell's executives, including Sehat Sutardja, Weili Dai, and Arturo Krueger.  
 26 The lawsuit was subsequently dismissed by the Administrative Law Judge in an  
 27 opinion dated June 24, 2009 on statute of limitations grounds since Gloss had filed  
 28 his lawsuit more than 90 days following his termination, which shortened period

1 Marvell had apparently forced Gloss to agree to when he started working at Marvell.

2 73. In addition to backdating stock options, the defendants have been  
 3 alleged to have engaged in substantial wrongdoing in litigation involving intellectual  
 4 property.

5 **III. The Individual Defendants' History of Alleged Theft of  
 6 Intellectual Property**

7 74. In April 2001, Marvell started talks to acquire telecommunications chip  
 8 technology from Jasmine Networks Inc., a San Jose-based competitor. As the  
 9 companies were negotiating, Marvell executives were conspiring with some of  
 10 Jasmine's senior managers to steal its trade secrets, a breach of contract lawsuit  
 11 Jasmine filed in September 2001 in Santa Clara County Superior Court alleged. In  
 12 its lawsuit, Jasmine contended that former Marvell director Manuel Alba directed  
 13 Marvell's action with the support of Sehat Sutardja. The suit sought \$40 million in  
 14 damages from Marvell. In a cross-complaint in 2005, Marvell rejected Jasmine's  
 15 allegations. Marvell alleged that Jasmine itself had stolen the technology and had  
 16 fraudulently misrepresented it as its own.

17 75. Jasmine's key evidence was a recorded conversation of Marvell General  
 18 Counsel Matthew Gloss, Vice President Kaushik Banerjee and in-house patent  
 19 attorney Eric Janofsky on August 16, 2001.

20 76. The three men had called Jasmine's lawyer, Virginia Wei, and had  
 21 gotten a voice mail greeting. Forgetting to hang up, the men discussed the legal peril  
 22 of Marvell's dealings with Jasmine. Their conversation was captured on Wei's voice  
 23 mail system. Gloss said, "Sehat doesn't go to jail, obviously" according to a  
 24 transcript published in a California appellate opinion written by Presiding Justice  
 25 Conrad Rushing in 2004. Referring to Alba, Gloss said, "Manuel might go to jail;  
 26 Manuel gets a black eye." *Id.* Later, Janofsky says, "If we took that IP on the  
 27 pretense of just evaluating it and put it in our product?" *Id.*

28 77. Justice Rushing found the remark about intellectual property showed

1 Marvell executives were discussing fraud. His ruling overturned a lower court order  
 2 that had barred Jasmine from using the recording. After proceeding in appellate  
 3 court, the case was remanded to Superior Court for trial.

4 **IV. The Individual Defendants Cause Marvell to Willfully Infringe  
 5 Patents Owned by Carnegie Mellon University**

6 78. During the relevant time period, CMU owned valuable patents that  
 7 Marvell willfully infringed, resulting in a jury verdict against Marvell and in CMU's  
 8 favor for \$1,169,140,271 in December 2012.<sup>7</sup> On March 31, 2014, the United States  
 9 District Court for the Western District of Pennsylvania enhanced that judgment to  
 10 approximately \$1.54 billion based on findings that Marvell willfully infringed CMU's  
 11 patents.

12 79. The patents that Marvell willfully infringed were critical to Marvell's  
 13 business. The jury made findings of fact that Marvell sold 2.34 billion chips that had  
 14 technology based on the infringed patents between March 6, 2003 and July 28,  
 15 2012. The average revenue for Marvell of such chips was \$4.42, and the average  
 16 profit per chip was \$2.16.

17 80. Because of the critical nature of the patents to Marvell's business, the  
 18 decision with respect to the infringement of CMU's patents were made by the  
 19 defendants named herein – the controlling directors and executives of Marvell, who  
 20 are all extremely knowledgeable about patents and patent law and several of whom  
 21 have personally registered hundreds of patents. They acted intentionally, willfully,  
 22 and in a dishonest manner with respect to the infringement of CMU's patents, and  
 23 their conduct has caused Marvell and its shareholders to be damaged in an amount  
 24 in excess of \$1.54 billion. Their conduct has further infringed rights personal to  
 25 Marvell's shareholders since the defendants' wrongdoing has interfered with  
 26 Marvell's ability to declare and pay dividends to Plaintiffs and the other Marvell

27  
 28 

---

 7 *Carnegie Mellon University v. Marvell Technology Group, Ltd.*, Case No. 09-  
 cv-0290 (W.D. Pa.).

1 shareholders.

2       81. Marvell knew about CMU's patents beginning at least in 2002. One of  
 3 the important engineers at Marvell who worked on the relevant technology was  
 4 Gregory Burd, who had joined Marvell in 1999. In January 2002, Burd sent two  
 5 emails to Toai Doan, who was then his boss at Marvell. Doan was a manager and  
 6 principal engineer of signal processing at Marvell and later Vice President of read  
 7 channel development. In his January 2002 emails to Doan, Burd told Doan that  
 8 CMU owned patents to the technology Marvell was interested in and working on,  
 9 which was referred to as the "Kavcic method" after its inventor of the same name  
 10 (Dr. Kavcic) from CMU. One of Burd's acting managers at Marvell was Dr. Nersi  
 11 Nazari. Nazari was Dr. Kavcic's main contact at Marvell.

12       82. Further, in August 2003, CMU's Technology Transfer representative  
 13 Carl Mahler sent a letter to Defendant Pantas Sutardja and to Marvell's General  
 14 Counsel, Matthew Gloss, inquiring as to whether Marvell would be interested in  
 15 licensing the relevant patents owned by CMU – US Patent No. 6,201,839 B1 and US  
 16 Patent No 6,438,180 B1 (referred to as the '180 and '839 patents, respectively).  
 17 CMU stated in the letter that "I have taken the liberty of including copies of these  
 18 patents along with this letter" and "I would be happy to work with you to negotiate a  
 19 license to these patents if that would be of interest to you."

20       83. Mahler had simultaneously sent the same letter to Fujitsu. Thus,  
 21 Fujitsu was also on notice of CMU's patents in this area. Fujitsu was one of  
 22 Marvell's customers in the read channel area, and thus, became concerned about  
 23 CMU's patents because it perceived Marvell's products to contain the same  
 24 technology covered by the CMU patents discussed in Mahler's letter. As a result, in  
 25 November 2004, Fujitsu employee Junya Suwanai wrote a letter to Marvell, noting  
 26 that Fujitsu had received Mahler's August 2003 letter offering to license CMU's  
 27 patented technology and asking Marvell whether its products infringed on CMU's  
 28 patents. Fujitsu asked for a response from Marvell by the end of the month. It is

1 not known whether Marvell ever responded (at least in writing) to Fujitsu's letter,  
 2 but the record from the proceedings in CMU's subsequent patent infringement case  
 3 indicates that Marvell did not produce any responsive letters.

4       84. Thus, beginning in at least 2002, Marvell had actual knowledge of  
 5 CMU's patents and intellectual property, and was given an opportunity to license the  
 6 patents.

7       85. In CMU's patent infringement trial, CMU was required to prove that  
 8 Marvell had the specific intent to encourage others to infringe CMU's patents, which  
 9 can be demonstrated if Marvell caused, urged, encouraged, or aided the infringing  
 10 conduct. On this point, the Court found that CMU introduced sufficient evidence at  
 11 trial that Marvell aided its customers' infringement by producing chips that used the  
 12 accused methods and instructed its customers to use the chips in infringing modes.  
 13 (Docket No. 677 at 180-183; Docket No. 678 at 91; Pl. Exs. 1913, 1918, 1919).<sup>8</sup>  
 14 Specifically, CMU entered into evidence emails, firmware, as well as programming  
 15 instructions for hardware showing that Marvell directed its customers, including  
 16 Western Digital, Samsung, and Toshiba, to use the chips in infringing modes. (Pl.  
 17 Exs. 730; 932; 1914; 1915; 1918; 1919).

18       86. Defendant Sehat Sutardja also had actual knowledge of CMU's patents  
 19 and willfully and intentionally caused Marvell to disregard those patents. At trial,  
 20 Sehat Sutardja testified that he was aware of the August 2003 letter from CMU and  
 21 stated that Marvell did not respond to such letter because Marvell was "not  
 22 interested in using the technology in our chip." (Docket No. 707 at 91).

23       87. Defendant Sehat Sutardja is an expert with respect to patents, having  
 24 been awarded over 260 patents. In addition to having served as Chairman of  
 25 Marvell since 2003, he has served at all relevant times as President, Chief Executive  
 26 Officer, and as a director of Marvell's U.S. operating subsidiary, Marvell

---

27       8 These references are to the docket in the CMU action, *Carnegie Mellon*  
 28 *University v. Marvell Technology Group, Ltd.*, Case No. 09-cv-0290 (W.D. Pa.).

1 Semiconductor, Inc. He is a very “hands on” manager, as he testified at the CMU  
 2 patent infringement trial, and as Marvell acknowledges on its website: “While  
 3 remaining deeply involved in the daily challenges of running a global growth  
 4 company, Dr. Sutardja participates heavily in Marvell’s engineering and marketing  
 5 efforts across analog, video processor, and microprocessor design while offering  
 6 input across all of the company’s other product lines.” During the relevant time  
 7 period, Dr. Sutardja generally held weekly staff meetings with his senior vice-  
 8 presidents, at which he was presented with weekly status reports.<sup>9</sup>

9       88. The defendants also had actual knowledge during the relevant time  
 10 period that Marvell was not able to successfully develop and patent its own  
 11 technology to address key issues with its products and that the key technology to  
 12 address such issues was held by CMU. For example, Defendant Sehat Sutardja  
 13 received an email on February 6, 2007 from Gregory Burd, who stated: “We did not  
 14 do a comparison with linear Viterbi since nowadays drives are dominated by media  
 15 noise and MNP or NLV is a must.” As Dr. Sutardja testified at trial, MNP and NLV  
 16 referred to technology covered by CMU’s patents. During the Relevant Period,  
 17 Marvell employees recognized that its own internal technology was woefully  
 18 inadequate and did not sufficiently address media noise problems. Marvell’s own  
 19 inferior technology was referred to by Marvell itself as “coffee warmers” because it  
 20 used so much electricity and was ineffective. As a result, Marvell did not use its own  
 21 defective and inadequate technology in its chips but instead used CMU’s technology,  
 22 without licensing it.

23       89. Further, after receiving actual notice of CMU’s patents, Defendants  
 24 Sehat and Pantas Sutardja also failed to cause Marvell’s employees to take any  
 25 significant action to investigate whether Marvell and others were infringing CMU’s  
 26 patents. At trial, the evidence demonstrated, to the contrary, that the Sutardja

---

27       28       <sup>9</sup> Dr. Sutardja testified that these meetings were attended, at a minimum, by  
 Marvell vice presidents Dr. Armstrong, Mr. Brennan, Mr. Doan, and Dr. Wu.

1 brothers encouraged Marvell employees to continue working on Marvell products  
 2 that infringed CMU's patents. As the Court noted in a September 23, 2013 order  
 3 denying Marvell's motion to set aside the verdict for insufficient evidence:

4 Despite knowing about the patents-in-suit, the evidence presented at  
 5 trial reveals that Marvell made little effort to determine whether it was  
 6 infringing these patents. Dr. Wu, Mr. Burd, and Mr. Doan all state that  
 7 they decided not to read the patent claims, even though email  
 8 correspondence indicates that both were aware that Dr. Kavcic had  
 9 patented his algorithm. (Pl. Ex. 280; Pl. Ex. 283). If believed, this  
 10 behavior is a clear sign they disregarded a high likelihood of  
 11 infringement. Once presented with the patents, Mr. Doan did not  
 12 conduct further investigations on his own, tell others to investigate or  
 13 send the patents to Marvell's legal team.<sup>72</sup> (Docket No. 761 at Jt. Ex. C at  
 14 125-130). Instead, he directed his employees to continue working to  
 15 capture the realized gain and reported that his employees would continue  
 16 to work on the "Kavcic model." (*Id.* at Ex. D at 190-191; Pl. Ex. 285).  
 17 This occurred around the time that he was promoted from his position as  
 18 principal engineer of the signal processing group to Vice President of  
 19 read channel development. (Docket No. 761 at Jt. Ex. C at 16-17). While  
 20 Marvell alleges that the MNP is a suboptimal version of Dr. Kavcic's  
 21 work, Dr. Wu's 2003 email to Doan stated that he and Burd were  
 22 implementing an approach that "turns out to be the original structure  
 23 that Kavcic proposed in his paper." (Pl. Ex. 366; Docket No. 677 at 134-  
 24 135).

25 90. The evidence at the CMU trial further established willfulness because it  
 26 was proven that Marvell failed to follow its own internal policy concerning steps to  
 27 be taken when risks regarding potential patent infringement are made known to the  
 28 Company:

29 These failed opportunities to investigate engendered a great deal of risk  
 30 that Marvell's engineers infringed CMU's patents. Moreover, the lack of  
 31 action by Marvell's employees does not conform to Marvell's own  
 32 purported IP policy, which according to the testimony of Dr. Armstrong,  
 33 Marvell's Vice President of Marketing, requires that any such  
 34 information about patents be forwarded to the legal department for  
 35 analysis. (Docket No. 761 at Jt. Ex. C at 294-295). Despite this, Dr.  
 36 Armstrong stated that he did not know whether the CMU Patents were  
 37 ever submitted to the legal department according to this policy. (*Id.* at  
 38 295, 299). He further testified that he was not aware of any internal

1 discussion about licensing the patents from CMU given Fujitsu's letter  
 2 request. (*Id.*)<sup>10</sup>

3 91. In finding that the evidence adduced at the CMU trial was sufficient to  
 4 establish willful infringement, the Court further stated:

5 Marvell's lack of inquiry about the possibility of infringement also meant  
 6 that it took no effort to avoid infringement of the subject patents. This  
 7 fact was specifically corroborated by Mr. Burd, who stated that he was  
 8 not aware of any measures being taken to stop using the CMU Patents.  
 9 (Docket No. 678 at 101). Marvell is a sophisticated entity with nearly  
 10 3,000 patents. (Docket No. 707 at 53). Yet, it took absolutely no steps to  
 11 investigate these patents before producing 2.3 billion chips, despite the  
 12 fact that the technology was *named* after Dr. Kavcic, one of the inventors  
 13 of the CMU Patents.<sup>73</sup> To this day, Marvell continues to use the  
 14 Accused Technology. In fact, at trial Mr. Burd testified that Marvell had  
 15 no plans to discontinue using the technology. (Docket No. 678 at 101).  
 16 Only as of July 2013—seven months after the verdict—is it beginning to  
 17 design around the technology. (Docket Nos. 889; 898).<sup>11</sup>

18 92. "Succinctly put, Burd presented his superiors at Marvell with a product  
 19 named "KavcicPP" and noted that Dr. Kavcic held a patent on such a detection  
 20 scheme, yet nothing was apparently done to investigate infringement, reach out to  
 21 Dr. Kavcic or CMU, or respond to CMU and Fujitsu's inquiries on same. Accordingly,  
 22 CMU has shown that Marvell's behavior created an objectively high risk of  
 23 infringement. *See Spectralytics, Inc. v. Cordis Corp.*, 649 F.3d 1336, 1348 (Fed. Cir.  
 24 2011) (failure to investigate the patent situation is a consideration that tends to  
 25 establish willful infringement)."<sup>12</sup>

26 93. Defendants' willful infringement and wrongful conduct was also noted  
 27 by the court in the CMU trial on several occasions. The Court noted that Marvell  
 28 tap-danced around a "reliance on counsel" defense. It did not assert an actual  
 29 reliance on counsel defense, apparently because it did not want to waive the  
 30 privilege and be forced to produce communications to and from its lawyers. But, as

---

26 <sup>10</sup> *See* September 23, 2013 Order Denying Marvell's Motion to Set Aside the  
 27 Verdict at 70.

28 <sup>11</sup> *See id.* at 70-71.

<sup>12</sup> *See id.* at 71.

1 the Court noted: “Marvell, however, has expressly stated throughout this litigation  
 2 that it is not raising advice of counsel as a defense to the willfulness claims.”  
 3 (Docket No. 174-1 at 77-78). To that end, the Court on December 20, 2012 ruled that  
 4 Marvell could not at trial:

5 [W]ithout putting the actual communications from counsel at issue –  
 6 argue that its receipt of a patent implies or suggests that Marvell’s  
 7 counsel returned a favorable opinion that Marvell’s NLD-type and MNP-  
 8 type chips and simulators and the Kavcic-Viterbi simulator do not  
 9 practice the patented methods of the asserted claims. (Docket No. 753).  
**Despite this, Marvell’s counsel attempted to imply at closing  
 that its engineers had vetted this patent with counsel based  
 on snippets of Dr. Wu’s testimony.** (Docket No. 759 at 79-80).<sup>13</sup>

10 94. In response to the attempt by Marvell’s counsel, at closing argument, to  
 11 suggest that Marvell had vetted the patent with counsel, the Court observed: “The  
 12 Court has doubts about the credibility of certain testimony regarding this  
 13 consultation and the reasonableness of this defense, given its years of involvement  
 14 with this matter.” In footnote 79 which accompanied the immediately preceding  
 15 quotation, the Court stated:

16 As the Court recounted in its opinion on Marvell’s Motion for a Mistrial,  
 17 (Docket No. 900), Dr. Wu during his testimony clenched his jaw, drank  
 18 an entire pitcher of water, generally appeared uncomfortable, and  
 19 continuously looked at Dr. Sutardja in the back of the courtroom  
 20 throughout his appearance as a witness. In this Court’s estimation, the  
 21 jury could have easily found Dr. Wu was not credible given his demeanor  
 22 on the stand. On this and all other areas of inquiry, the jury was charged  
 23 to weigh witness testimony and give it the appropriate weight it deserved  
 24 or discredit the testimony completely. *See, e.g., Barber v. CSX  
 25 Distribution Servs.*, 68 F.3d 694, 700 (3d Cir. 1995).

26 95. In addition to the actual knowledge of Marvell’s patent infringement by  
 27 Defendants Sehat and Pantas Sutardja, the other director defendants either knew or  
 28 recklessly disregarded Marvell’s infringement of CMU’s patents. Indeed, in 2009  
 CMU filed its patent infringement lawsuit against Marvell. Thus, at least beginning  
 in 2009, director Defendants Gromer, Kassakian, Krueger and Thakur, as well as

---

13 *See id.* at 74 (emphasis added).

1 Weili Dai, had actual knowledge that CMU alleged infringement by Marvell. These  
 2 Individual Defendants are all highly sophisticated in technology companies and  
 3 patents. For example, Dr. Thakur has been issued close to 300 patents. He is  
 4 currently executive vice president and general manager of the Silicon Systems Group  
 5 at Applied Materials, Inc., which comprises the entire portfolio of semiconductor  
 6 manufacturing systems at Applied Materials. In this role, Dr. Thakur is responsible  
 7 for strengthening Applied Materials' market in its core wafer fabrication equipment  
 8 markets. Dr. Thakur holds a B.S. with honors in Electronics and  
 9 Telecommunications Engineering from the National Institute of Technology,  
 10 Kurukshetra, India, an M.S. in Electrical Engineering from the University of  
 11 Saskatchewan, Canada and a Ph.D. in Electrical Engineering from the University of  
 12 Oklahoma.

13       96.   Likewise, Defendant Krueger has more than 40 years of experience in  
 14 the international semiconductor industry and acquired a wealth of experience in  
 15 complex systems architecture, semiconductor design and development, operations,  
 16 and international marketing, as well as general management of a large company.  
 17 Krueger holds a MS in Electrical Engineering from the Institute of Technology in  
 18 Switzerland and has studied Advanced Computer Science at the University of  
 19 Minnesota.

20       97.   Defendant Kassakian holds S.B., S.M., E.E. and Sc.D. degrees from  
 21 MIT and has been a member of the faculty of Electrical Engineering and Computer  
 22 Science at MIT since 1973 and served as director of the MIT Laboratory for  
 23 Electromagnetic and Electronic Systems from 1991 to 2009. Dr. Kassakian is the  
 24 founding President of the IEEE Power Electronics Society and is a member of the  
 25 National Academy of Engineering. Marvell's website touts Dr. Kassakian's  
 26 "expertise in the semiconductor field and academic experience related to the  
 27 technology sector" as positive factors that qualify him to sit on Marvell's Board.

28       98.   Likewise, Defendant Gromer is sophisticated in the fields of

1 engineering and patents. He received his undergraduate degree and Ph.D. in  
 2 Physics from the University of Stuttgart, Germany. Gromer is the retired President  
 3 of Tyco Electronics Ltd., an electronics company, a position that he held from April  
 4 1999 until December 31, 2007. Dr. Gromer formerly held senior management  
 5 positions from 1983 to 1998 at AMP Incorporated (acquired by Tyco International in  
 6 April 1999), including Senior Vice President of Worldwide Sales and Services,  
 7 President of the Global Automotive Division, Vice President of Central and Eastern  
 8 Europe and General Manager of AMP.

9       99.   Defendant Dai had actual knowledge of these facts because of her  
 10 position with Marvell and because of daily communications she had with her  
 11 husband, Defendant Sehat Sutardja.

12       100.   Thus, because of their educational background, work experience,  
 13 relationship with Sehat and Pantas Sutardja, and experience in applying for patents  
 14 and/or reviewing the value and importance of patents to the companies they have  
 15 worked for, Defendants Gromer, Kassakian, Krueger, Dai and Thakur were  
 16 particularly suited to evaluate the materiality of the relevant patents and technology  
 17 to Marvell's business, revenues, and profits. When CMU sued Marvell for patent  
 18 infringement in 2009, Defendants Gromer, Kassakian, Krueger, Dai and Thakur  
 19 were required to conduct an investigation into the allegations and determine if they  
 20 had merit. Upon information and belief, they conducted such an investigation and  
 21 determined that Marvell had actually infringed the patents, or that there was a  
 22 significant likelihood that Marvell had infringed CMU's patents. Nonetheless, they  
 23 failed to take appropriate action.

24       101.   Among other things, upon being presented with evidence of Marvell's  
 25 infringement, Defendants Gromer, Kassakian, Krueger, Dai, and Thakur could have  
 26 and should have caused Marvell to settle the case at a reasonable cost. The evidence  
 27 at trial demonstrates that CMU acted reasonably at all times and would have  
 28 accepted a reasonable settlement offer. Marvell's own expert at trial suggested that

1 a reasonable license for CMU's patents would be a one-time royalty of \$250,000.  
 2 Tellingly, Marvell rejected CMU's reasonable offers to allow Marvell to license its  
 3 patents back in 2003.

4       102. While it is unknown what Marvell could have negotiated as a  
 5 reasonable license fee back in 2003, any such license would have cost Marvell far  
 6 less than the \$1 billion verdict. Moreover, again, once CMU filed its lawsuit in 2009,  
 7 Marvell could have negotiated a reasonable settlement far below \$1 billion. It  
 8 refused to do so and instead actually continued to willfully infringe CMU's patents,  
 9 even after the lawsuit was filed. As Judge Fischer noted, ***the director***  
 10 ***defendants, including Defendants Gromer, Kassakian, Krueger, Dai***  
 11 ***and Thakur, caused Marvell to willfully infringe CMU's patents even***  
 12 ***after the jury verdict was returned in December 2012. Marvell did not***  
 13 ***stop selling the infringing chips until July 2013, six months after the***  
 14 ***jury verdict was entered.***

15       103. Thus, Defendants Gromer, Kassakian, Krueger, Dai, and Thakur  
 16 breached their duty of candor and acted in bad faith and in a dishonest manner by  
 17 refusing to cause Marvell to settle the CMU lawsuit for a reasonable sum and by  
 18 increasing Marvell's damages by causing Marvell to continue to sell the infringing  
 19 chips even after the jury verdict was entered.

20       104. Moreover, by refusing to settle the CMU suit in bad faith, Defendants  
 21 Gromer, Kassakian, Krueger, Dai, and Thakur have now damaged Marvell further, in  
 22 an amount in excess of \$1.54 billion. Had Defendants Gromer, Kassakian, Krueger,  
 23 Dai and Thakur acted reasonably and in good faith and settled the CMU lawsuit for a  
 24 reasonable amount, Marvell would have avoided any exposure for willful  
 25 infringement.

26       105. Analysts noted the huge damage that has been caused to Marvell due to  
 27 the CMU judgment, and that will continue to be caused. A January 9, 2013 article in  
 28 GMI Ratings entitled "Can Only SpiderMan Save Marvell Technology Group?"

1 noted:

2 While it is important to note that the \$1.17 billion verdict is subject to  
 3 appeal, there is also a possibility that the damages could triple to about  
 4 \$3.5 billion—an amount that is dangerously close to the company's  
 5 current market cap value of \$4.2 billion—since jurors found Marvell's  
 6 patent infringement was willful. In addition to the \$1.17 billion jury  
 7 award, Marvell is required to make 50-cent royalty payments on all  
 8 infringing HD controller chips sold in the future. According to a report  
 9 on Seeking Alpha, ***the CMU patents “currently encompass all of  
 10 Marvell’s HD chips [and] the per-chip royalty will result in  
 roughly a 20% hit to operating margins on their HD  
 controller business.*** The report goes on to say that ***since the HD  
 controller business makes up approximately 50% of Marvell’s  
 sales, the ongoing impact to earnings will be astounding, and  
 could result in a 25% reduction in net earnings for Marvell as  
 a whole going forward.***

11 106. With respect to ongoing royalties, on May 1, 2014, Marvell and CMU  
 12 filed a Joint Report with Judge Fischer indicating that Marvell's sales of infringing  
 13 chips during the period November 3, 2013 through February 1, 2014 was in excess of  
 14 \$390 million.<sup>14</sup> Thus, because the Judgment calls for Marvell to pay a royalty of  
 15 \$0.50 per infringed chip sold, Marvell is exposed to ongoing royalty damages of at  
 16 least \$195 million in addition to the amount of the Judgment itself.

17 **V. Materially False and Misleading Statements Issued During the  
 18 Relevant Period**

19 107. In addition to willfully infringing CMU's patents during the Relevant  
 20 Period, the Individual Defendants caused the Company to issue false and misleading  
 21 statements that failed to disclose the fact that Marvell was willfully infringing CMU's  
 22 patents and instead falsely stated or implied that Marvell had patents covering all its  
 23 key technology and/or had paid appropriate licenses to persons who held patents for  
 24 the relevant technology.

25 108. False Statements in Marvell's 2007 Annual Report: Marvell's 2007  
 26 Annual Report was filed with the SEC on Form 10-K and mailed to Marvell's

27 28 <sup>14</sup> Marvell and CMU disagreed slightly on the exact sales figures. Marvell listed  
 total sales during this time period of \$390,726,473, while CMU listed sales of  
 \$392,029,138.

1 shareholders on or about July 2, 2007. It was drafted, reviewed, approved, and  
 2 signed by the Individual Defendants Sehat Sutardja, Pantas Sutardja, Arturo  
 3 Krueger, and non-defendant Michael Tate, among others. In the 2007 Annual  
 4 Report, Individual Defendants Sehat Sutardja, Pantas Sutardja, and Arturo Krueger  
 5 caused Marvell to make the following false and misleading statements about  
 6 Marvell's intellectual property and patents:

7 **Intellectual Property**

8 Our future revenue growth and overall success depend in large part on  
 9 our ability to protect our intellectual property. We rely on a combination  
 10 of patents, copyrights, trademarks, trade secret laws, contractual  
 11 provisions and licenses to protect our intellectual property. We also  
 12 enter into confidentiality agreements with our employees, consultants,  
 13 suppliers and customers and seek to control access to, and distribution  
 14 of, our documentation and other proprietary information. Despite these  
 15 precautions, it may be possible for a third-party to copy or otherwise  
 16 obtain and use our products and technology without authorization,  
 17 develop similar technology independently or design around our patents.

18 ***In addition, we often incorporate the intellectual property of  
 19 other companies into our designs, and we have certain  
 20 obligations with respect to the non-use and non-disclosure of  
 21 their intellectual property.*** It is possible, however, that the steps  
 22 taken by us to prevent misappropriation or infringement of our  
 23 intellectual property or our customers' intellectual property may not be  
 24 successful.

25 **109. Why the statement was false:** The italicized statement above in  
 26 Marvell's 2007 Annual Report was false and misleading because it failed to disclose  
 27 to Marvell's shareholders that Marvell ***had actually incorporated CMU's  
 28 intellectual property into its chip designs but failed to pay a licensing  
 fee to CMU for use of CMU's patents.*** The Individual Defendants, as alleged in  
 great detail herein, knew this statement, as well as the further statements identified  
 below, were false because they had received notice of CMU's patents in 2002 and  
 2003, along with an invitation to license the patents, but declined to license the  
 21 patents and instead instructed Marvell employees to incorporate CMU's intellectual  
 22 property into Marvell's chip designs illegally, and without paying the necessary  
 23 license. The amounts involved were highly material to Marvell's results and  
 24

1 operations, as reflected in the eventual jury verdict against Marvell for willful patent  
 2 infringement.

3       110. False Statement: Marvell's 2007 Annual Report also stated:

4           As of January 27, 2007, we have been issued or have acquired 406  
 5           United States patents and 72 non-United States patents on various  
 6           aspects of our technology, with expiration dates ranging from 2008 to  
 7           2025. We have filed a number of additional patent applications in the  
 8           United States and other countries.

9           We have expended and will continue to expend considerable resources in  
 10          establishing a patent position designed to protect our intellectual  
 11          property. While ***our ability to compete is enhanced by our***  
 12          ***ability to protect our intellectual property***, we believe that in  
 13          view of the rapid pace of technological change, ***the combination of***  
 14          ***the technical experience and innovative skills of our***  
 15          ***employees may be as important to our business as the legal***  
 16          ***protection of our patents and other proprietary information.***

17           From time to time, we may desire or be required to renew or to obtain  
 18          licenses from third parties in order to further develop and effectively  
 19          market commercially viable products. We cannot be sure that any  
 20          necessary licenses will be available or will be available on commercially  
 21          reasonable terms.

22       111. Why the statements were false: The italicized statement above in  
 23          Marvell's 2007 Annual Report was false and misleading because it suggested that  
 24          Marvell had intellectual property or patents covering all the technology it  
 25          incorporated into its chip designs and chips. The statements told shareholders and  
 26          the stock market that Marvell's business and success were the product of ***its***  
 27          ***patents***, and that its ability to protect ***its intellectual property*** enhanced  
 28          Marvell's "ability to compete" in the marketplace and vis-à-vis its competitors. The  
 29          statements also falsely told investors that "the technical experience and innovative  
 30          skills of our employees may be as important to our business as the legal protection of  
 31          our patents and other proprietary information." Both of these statements were false  
 32          and misleading half-truths since: (1) Marvell did not disclose that a huge and  
 33          material portion of its chip designs and chips relied on CMU's patents, which  
 34          Marvell was willfully infringing, and not on any patents or IP owned by Marvell; and  
 35          (2) Marvell's employees, regardless of whether they did or did not have experience

1 and innovate skills in general, were not using any of their innovative skills or  
 2 experience in developing the Company's NLD, MNP, and EMNP chips (as well as the  
 3 simulators associated with developing such chips and the related technology)<sup>15</sup> but  
 4 instead were intentionally and illegally copying CMU's intellectual property and  
 5 patents without negotiating or paying a licensing fee to CMU. Moreover, the  
 6 statement "From time to time, we may desire or be required to renew or to obtain  
 7 licenses from third parties in order to further develop and effectively market  
 8 commercially viable products" was false and misleading because the Individual  
 9 Defendants knew, but omitted to disclose, that Marvell was intentionally and  
 10 illegally copying CMU's intellectual property and patents without negotiating or  
 11 paying a licensing fee to CMU.

12       112. False Statement: Marvell's 2007 Annual Report also falsely stated that  
 13 its products were based on its own proprietary technology, and failed to disclose that  
 14 the products were actually based on CMU's patented and proprietary technology and  
 15 that Marvell was willfully infringing CMU's patents. The 2007 Annual Report  
 16 specifically made these statements with respect to Marvell's Read Channel circuits  
 17 and System on a Chip ("SOC") product, an integrated drive electronics platform.  
 18 Both Marvell's Read Channel circuits and its SOC products incorporated Marvell's  
 19 MNP, EMNP-type, and NLD type chips, all of which were proven at the CMU patent  
 20 trial to infringe CMU's patents. With respect to Marvell's Read Channel and SOC  
 21 products, the 2007 Annual Report stated:

22       **Our Markets and Products**

23       We target computers, communications-related equipment and consumer  
 24 devices that require integrated circuit devices for high-speed data  
 25 storage, transmission, and management. We also target a broad range of  
 26 electronic products that can utilize our power management solutions.  
 27 Additionally, we are developing new products that are targeted for new  
 28 markets that we currently do not serve. Our current product offerings

---

15 CMU's patents relate to read-channel integrated circuit devices and the HDD  
 28 products incorporating such devices.

1 are primarily targeted at three main markets: business enterprise,  
 2 consumer and emerging markets.

3 ***We offer our customers in these markets a wide range of  
 4 integrated circuit solutions using proprietary  
 5 Communications Mixed-Signal Processing, or CMSP, and  
 6 digital signal processing technologies. We are applying our  
 7 analog, mixed-signal, digital signal processing, embedded  
 8 microprocessor and complex digital design technologies in a  
 9 variety of applications.*** Our broad product portfolio consists of  
 10 storage, switching, transceivers, cellular and handheld, wireless, PC  
 11 connectivity, gateways, communications controllers and power  
 12 management products.

## 13 **Storage Products**

14 We offer a broad range of storage products for hard disk drive and tape  
 15 drive electronics and storage interconnect technology. Also, we recently  
 16 developed our first optical storage products for DVD recorders that will  
 17 be used in computer applications.

18 **Read Channel.** A read channel is an integrated circuit that provides  
 19 the interface between the analog signals stored on magnetic disk drives  
 20 and the digital signals that computers can understand and manipulate.  
***The performance of the read channel normally drives the  
 21 performance of the overall storage system. We utilize  
 22 advanced mixed-signal and digital signal processing  
 23 technologies in our array of partial response maximum  
 24 likelihood, or PRML read channel products. Our technology  
 25 incorporates an efficient data-encoding scheme in addition to  
 26 advanced digital filtering and data-detection techniques.*** Our read channel products are designed to allow customers to achieve high  
 27 areal density in addition to fast data transfer rates for their hard disk  
 28 drives. ***Our read channels utilize custom digital and analog  
 29 blocks running at a very high frequency while achieving low  
 30 power consumption.***

31 Our read channel integrated circuits target specific feature and  
 32 performance requirements of the enterprise, desktop and mobile  
 33 computing markets. Our strategy is to consolidate the signal processing  
 34 algorithms required by each of our different market segments into a  
 35 single integrated circuit design. This consolidation can result in cost  
 36 savings and reduced product line complexity.

37 **System-On-Chip.** ***Our integrated drive electronics platform is a  
 38 flexible system-on-a-chip, or SOC solution that provides  
 39 increased performance, reduced power consumption and cost  
 40 savings essential for next-generation hard disk drives.  
 41 Utilizing our leading-edge read channel physical layer  
 42 devices*** as the core for integration, we have the flexibility to either add

any number of functional blocks available in our portfolio or to integrate customer provided intellectual property. With our high data transfer rates, our integrated SOC platform provides solutions that have the ability to span multiple product generations, allowing for risk-reduction, cost savings and accelerated time-to-market. Our integrated SOC platform is designed to provide a solution for enterprise, desktop and mobile systems. Our current SOC products incorporate the read channel, hard disk controller, embedded memory and one or more microprocessors into a single integrated circuit.

113. Why the statements were false – The statements referenced above about Marvell’s Read Channel and SOC products were false and misleading because they stated and/or implied that such products were based on Marvell’s own proprietary technology and patents, and did not disclose that Marvell’s Read Channel circuits and its SOC products incorporated Marvell’s MNP, EMNP-type, and NLD type chips, all of which infringed CMU’s patents. Marvell used CMU’s technology and patents in its Read Channel and SOC products precisely because CMU’s technology and patents were far superior to any technology Marvell had developed. Indeed, the evidence at the CMU trial demonstrated that Marvell’s technology for the Read Channel products was referred to by Marvell employees as “coffee warmers” because it used so much power. CMU’s technology, in stark contrasts, allowed higher performance and less power consumption. Thus, the statement quoted above from the 2007 Annual Report that “Our read channels utilize custom digital and analog blocks running at a very high frequency while achieving low power consumption” was false and misleading because Defendants failed to disclose that it was CMU’s technology, not Marvell’s, that was the cause of these benefits, and that Marvell was using CMU’s patented technology without negotiating and paying a necessary license or royalty.

114. Statements in Marvell’s 2008 Annual Report: Marvell’s 2008 Annual Report was filed with the SEC on Form 10-K and mailed to Marvell’s shareholders on or about March 28, 2008. It was drafted, reviewed, approved, and signed by the Individual Defendants Sehat Sutardja, Pantas Sutardja, Arturo Krueger, and Juergen Gromer, among others. In the 2008 Annual Report, Individual Defendants

1 Sehat Sutardja, Pantas Sutardja, Arturo Krueger, and Juergen Gromer caused  
 2 Marvell to make the same false and misleading statements as were made in the 2007  
 3 Annual Report. A true and correct copy of such false statements from the 2008  
 4 Annual Report is attached hereto as **Ex. 1**, and incorporated herein by reference.  
 5 Those statements were false and misleading for the same reasons stated *supra* in  
 6 paragraphs 109, 111, and 113.

7       115. False Statements in 2009 Annual Report: Marvell's 2009 Annual  
 8 Report was filed with the SEC on Form 10-K and mailed to Marvell's shareholders  
 9 on or about March 31, 2009. It was drafted, reviewed, approved, and signed by the  
 10 Individual Defendants Sehat Sutardja, Pantas Sutardja, John G. Kassakian, Arturo  
 11 Krueger, and Juergen Gromer, and non-defendant Clyde R. Hosein, among others.  
 12 In the 2009 Annual Report, Individual Defendants Sehat Sutardja, Pantas Sutardja,  
 13 John G. Kassakian, Arturo Krueger, and Juergen Gromer caused Marvell to make  
 14 the same false and misleading statements as those made in the 2007 and 2008  
 15 Annual Reports. A true and correct copy of such false statements from the 2009  
 16 Annual Report is attached hereto as **Ex. 2**, and incorporated herein by reference.  
 17 Those statements were false and misleading for the same reasons stated *supra* in  
 18 paragraphs 109, 111, and 113.

19       116. False Statements in Marvell's 2010 Annual Report: Marvell's 2010  
 20 Annual Report was filed with the SEC on Form 10-K and mailed to Marvell's  
 21 shareholders on or about March 30, 2010. It was drafted, reviewed, approved, and  
 22 signed by the Individual Defendants Sehat Sutardja, Pantas Sutardja, John G.  
 23 Kassakian, Arturo Krueger, and Juergen Gromer, and non-defendant Clyde R.  
 24 Hosein, among others. In the 2010 Annual Report, Individual Defendants Sehat  
 25 Sutardja, Pantas Sutardja, John G. Kassakian, Arturo Krueger, and Juergen Gromer  
 26 caused Marvell to make substantially similar false and misleading statements as  
 27 those made in the 2007-2009 Annual Reports. A true and correct copy of such false  
 28 statements from the 2010 Annual Report is attached hereto as **Ex. 3**, and

1 incorporated herein by reference. Those statements were false and misleading for  
 2 the same reasons stated *supra* in paragraphs 109, 111, and 113.

3       117. The statements in the 2010 Annual Report concerning Marvell's Read  
 4 Channel products were slightly different than in previous years, and emphasized to  
 5 even a greater degree that it was Marvell's technology and that such technology gave  
 6 it a competitive edge. The 2010 Annual Report stated:

7           Overview

8           We are a fabless semiconductor provider of high-performance  
 9 application-specific standard products. Our core strength of expertise is  
 10 the development of complex System-on-a-Chip ("SoC") devices  
 11 leveraging our extensive technology portfolio of intellectual property in  
 12 the areas of analog, mixed-signal, digital signal processing and embedded  
 13 ARM-based microprocessor integrated circuits.

14       118. The 2010 Annual Report also stated:

15           Storage Products

16           We offer a broad range of storage products targeted for hard disk drives,  
 17 tape drive electronics, optical disk drives, solid-state flash drives and  
 18 storage subsystems technology. We offer both discrete components  
 19 targeted at specific storage-class requirements, as well as complex SoC  
 20 solutions, which integrate multiple functional blocks onto a single device.

21           ***Storage System-on-a-Chip: Our integrated drive electronics  
 22 platform is a flexible SoC solution that provides increased  
 23 performance, reduced power consumption and cost savings  
 24 essential for next-generation hard disk drives.*** We provide  
 25 Storage SoC solutions for enterprise, desktop and mobile storage  
 26 systems.

27           Utilizing ***our leading-edge read channel devices*** as the core for  
 28 integration, we have the flexibility to either add any number of functional  
 29 blocks available in our portfolio or to integrate customer provided  
 30 intellectual property. With our high data transfer rates, ***our advanced  
 31 SoC platform*** provides solutions that have the ability to span multiple  
 32 product generations, allowing for product life cycle risk-reduction, lower  
 33 cost of ownership and accelerated time-to-market.

34           ***Our current SoC products incorporate the read channel, hard disk  
 35 controller ("HDC"), embedded memory and one or more Marvell  
 36 designed ARM-microprocessors into a single integrated circuit.***

37           ***Read Channel:*** A read channel is a mixed-signal integrated circuit that  
 38 provides the interface between the analog signals stored on magnetic disk drives

1 and the digital signals that computers can understand and manipulate. ***The***  
 2 ***performance of the read channel is a key factor to the overall***  
 3 ***performance of the hard disk drive storage system.*** Read channel  
 4 performance is measured as a function of the signal-to-noise ratio (“SNR”). The  
 5 higher the SNR value of a read channel circuit, the better the circuit is able to  
 6 separate valid data from system induced noise. ***Our ability to consistently***  
 7 ***develop multiple generations of read channel circuits with industry***  
 8 ***leading SNR performance has enabled our customers to improve***  
 9 ***finished drive yields and to yield higher density drives given a fixed***  
 10 ***aerial density platter.***

11 ***In the development of our read channel products we utilize***  
 12 ***advanced mixed-signal and digital signal processing***  
 13 ***technologies.*** Our read channel devices utilize a variety of advanced  
 14 signaling algorithms including advanced partial response maximum  
 15 likelihood (Advanced PMRL) or the low density parity check (“LDPC”)  
 16 algorithm. We anticipate the majority of our future storage SoC solutions  
 17 for high-density drives will be based on LDPC read channel technology.  
 18 Our technology incorporates an efficient data-encoding scheme in  
 19 addition to advanced digital filtering and data-detection techniques. Our  
 20 read channel products are designed to allow customers to achieve high  
 21 areal density in addition to fast data transfer rates for their hard disk  
 22 drives. Our read channels utilize custom digital and analog blocks  
 23 running at a very high frequency while achieving low power  
 24 consumption.

25 119. **Why the statements were false** – These statements in the 2010 Annual  
 26 Report were false and misleading for the same reasons noted in paragraphs 109, 111,  
 27 and 113.

28 120. **False Statements in the 2011 Annual Report:** Marvell’s 2011 Annual  
 1 Report was filed with the SEC on Form 10-K and mailed to Marvell’s shareholders  
 2 on or about March 25, 2011. It was drafted, reviewed, approved, and signed by the  
 3 Individual Defendants Sehat Sutardja, Pantas Sutardja, John G. Kassakian, Arturo  
 4 Krueger, Juergen Gromer, and non-defendant Clyde R. Hosein, among others. In  
 5 the 2011 Annual Report, Individual Defendants Sehat Sutardja, Pantas Sutardja,  
 6 John G. Kassakian, Arturo Krueger, Juergen Gromer caused Marvell to make  
 7 substantially similar false and misleading statements as those made in the 2007-  
 8 2010 Annual Reports. A true and correct copy of such false statements from the  
 9 2011 Annual Report is attached hereto as **Ex. 4**, and incorporated herein by  
 10 reference. Those statements were false and misleading for the same reasons stated

1 *supra* in paragraphs 109, 111, and 113.

2 121. The statements in the 2011 Annual Report concerning Marvell's Read  
 3 Channel products were slightly different than in previous years, and emphasized to  
 4 even a greater degree that it was Marvell's technology and that such technology gave  
 5 it a competitive edge. The 2011 Annual Report stated:

6 **Read Channel:** A read channel is a mixed-signal integrated circuit that  
 7 provides the interface between the analog signals stored on magnetic disk  
 8 drives and the digital signals that computers can understand and  
 9 manipulate. The performance of the read channel is a key factor to the  
 10 overall performance of the hard disk drive storage system. Read channel  
 11 performance is measured as a function of the signal-to-noise ratio  
 12 ("SNR"). ***The higher the SNR value of a read channel circuit, the better the circuit is able to separate valid data from system induced noise. Our ability to consistently develop multiple generations of read channel circuits with industry leading SNR performance has enabled our customers to improve finished drive yields and to yield higher density drives given a fixed areal density platter.***

13  
 14 ***In the development of our read channel products we utilize advanced mixed-signal and digital signal processing technologies. Our read channel devices utilize a variety of advanced signaling algorithms including advanced partial response maximum likelihood or the low density parity check ("LDPC") algorithm. We anticipate the majority of our future storage SoC solutions for high-density drives will be based on LDPC read channel technology. Our technology incorporates an efficient data-encoding scheme in addition to advanced digital filtering and data-detection techniques.*** Our read  
 15 channel products are designed to allow customers to achieve high areal  
 16 density in addition to fast data transfer rates for their hard disk drives.  
 17 ***Our read channels utilize custom digital and analog blocks running at a very high frequency while achieving low power consumption.***

18  
 19 122. **Why the statements were false:** The italicized statements above in  
 20 Marvell's 2011 Annual Report were false and misleading because they suggested  
 21 Marvell had developed and could consistently develop multiple generations of  
 22 superior Read Channel products based on its own proprietary technology. This was  
 23 false because Marvell's Read Channel products did not rely upon Marvell's  
 24 technology for their advances but instead relied upon infringed CMU patents. The  
 25  
 26  
 27  
 28

1 statements were also false because they failed to disclose to Marvell's shareholders  
 2 that the relevant read channel products were actually developed based on  
 3 technologies belonging to CMU which were protected by patent but were literally  
 4 and willfully infringed by Marvell.

5       123. False Statements in Marvell's 2012 Annual Report: Marvell's 2012  
 6 Annual Report was filed with the SEC on Form 10-K and mailed to Marvell's  
 7 shareholders on or about March 27, 2012. It was drafted, reviewed, approved, and  
 8 signed by the Individual Defendants Sehat Sutardja, Pantas Sutardja, John G.  
 9 Kassakian, Arturo Krueger, and Juergen Gromer, and non-defendant Clyde R.  
 10 Hosein, among others. In the 2012 Annual Report, Individual Defendants Sehat  
 11 Sutardja, Pantas Sutardja, John G. Kassakian, Arturo Krueger, and Juergen Gromer  
 12 caused Marvell to make substantially similar false and misleading statements as  
 13 those made in the prior annual reports. The exact false statements made are  
 14 reflected in the highlighted portions of the 2012 Annual Report which are attached  
 15 hereto as **Ex. 5**. Those statements were false and misleading for the same reasons  
 16 stated *supra* in paragraphs 109, 111, and 113.

17       124. False Statements in the 2013 Annual Report: Marvell's 2013 Annual  
 18 Report was filed with the SEC on Form 10-K and mailed to Marvell's shareholders  
 19 on or about March 29, 2013. It was drafted, reviewed, approved, and signed by the  
 20 Individual Defendants Sehat Sutardja, Pantas Sutardja, John G. Kassakian, Arturo  
 21 Krueger, Juergen Gromer, Randhir Thakur and non-defendant Brad D. Feller. In  
 22 the 2013 Annual Report, Individual Defendants Sehat Sutardja, Pantas Sutardja,  
 23 John G. Kassakian, Arturo Krueger, Juergen Gromer, and Randhir Thakur caused  
 24 Marvell to make substantially similar false and misleading statements as those made  
 25 in the prior annual reports noted above. The exact false statements made are  
 26 reflected in the highlighted portions of the 2013 Annual Report which are attached  
 27 hereto as **Ex. 6**. Those statements were false and misleading for the same reasons  
 28 stated *supra* in paragraphs 109, 111, and 113.

125. False Statements in the 2014 Annual Report: Marvell's 2014 Annual Report was filed with the SEC on Form 10-K and mailed to Marvell's shareholders on or about March 27, 2014. It was drafted, reviewed, approved, and signed by the Individual Defendants Sehat Sutardja, John G. Kassakian, Arturo Krueger, Juergen Gromer, Randhir Thakur and non-defendant Michael Rashkin. In the 2013 Annual Report, Individual Defendants Sehat Sutardja, John G. Kassakian, Arturo Krueger, Juergen Gromer, and Randhir Thakur caused Marvell to make substantially similar false and misleading statements as those identified in the prior annual reports identified above. The exact false statements made are reflected in the highlighted portions of the 2014 Annual Report which are attached hereto as **Ex. 7**. Those statements were false and misleading for the same reasons stated *supra* in paragraphs 109, 111, and 113.

## **THE UNJUST COMPENSATION PAID TO THE INDIVIDUAL DEFENDANTS**

15        126. During the time they were causing Marvell to willfully infringe CMU's  
16        patents and exposing Marvell to billions of dollars in damages, the Individual  
-        Defendants were paid excessive and unjust compensation.

18        127. During the relevant time period, most of the Individual Defendants'  
19 compensation from Marvell was incentive-based compensation. As such, it was only  
20 earned if Marvell met or exceeded certain performance goals. Those goals, and the  
21 formulas governing whether the Individual Defendants' incentive-based  
22 compensation was earned for each relevant year, are set forth in the Company's  
23 proxy statements on Form 14A filed with the SEC.

24 128. For example, for the performance-based awards (options or RSUs)  
25 given by Marvell during the relevant time period to Sehat Sutardja, whether Sutardja  
26 received the awards and, if so, the amount, was based on (a) earnings per share  
27 during 2008 (Marvell had to realize EPS of at least \$1.06); (b) Relative Operating  
Margin in 2009 (operating margin achieved by Marvell for the year had to be at or

1 above the 60th percentile of a Performance Peer Group); (c) Revenue and Operating  
 2 Margin for 2011 (revenue growth had to be 10-25% higher than 2010; non-GAAP  
 3 operating margin had to be between 23.5% and 26%). In the 2010 proxy statement,  
 4 Marvell also disclosed that 75% of Sehat Sutardja's compensation was tied to  
 5 performance of the Company, and that the performance-based compensation would  
 6 only be realized if Marvell achieved performance goals that aligned with the 75<sup>th</sup>  
 7 percentile of a peer group of other companies: "The executive compensation  
 8 committee approved a target compensation package for Dr. Sehat Sutardja for fiscal  
 9 2011 that aligns with the 75th percentile of the peer group. This package is intended  
 10 to have approximately 75% of total compensation value tied to performance, and will  
 11 only align with the 75th percentile of the peer group if Dr. Sehat Sutardja achieves  
 12 performance conditions." *See* Marvell's 2010 Proxy Statement at 28. In describing  
 13 why Marvell's Executive Compensation Committee (Defendants Gromer, Kassakian,  
 14 and Krueger) awarded a generous compensation package to Dr. Sehat Sutardja, the  
 15 Proxy stated that Sutardja "sets our strategic vision and manages the day-to-day  
 16 operations of the business. Importantly, he plays a lead role in mapping our  
 17 innovation and R&D vision which is foundational to future shareholder value  
 18 creation. With over 150 patents, his personal leadership in the advancement of our  
 19 technology is critical to achieving our business objectives." *See id.* at 28-29. This  
 20 statement was false and misleading because the Proxy did not reveal that Sutardja's  
 21 "personal leadership" in the management of the day-to-day operations of Marvell  
 22 included willful infringement of the CMU patents, and that far from contributing to  
 23 "future shareholder value creation," Sutardja's dishonest and willful patent  
 24 infringement would result in the destruction of shareholder value to the tune of over  
 25 \$1 billion.

26       129. Pantas Sutardja's performance-based awards (options or RSUs) were  
 27 also premised on Marvell achieving certain benchmarks. Pantas Sutardja's awards  
 28 were based on EPS in 2008 (Marvell had to achieve EPS of \$1.06 or more) and were

1 based on revenue growth in 2011.

2 130. Pursuant to the formulas and factors set forth in Marvell's proxy  
 3 statements, Defendants Sehat Sutardja, Weili Dai, and Pantas Sutardja were paid  
 4 the following incentive-based compensation during the indicated years:

Position	Fiscal Year	Salary (\$)	Bonus (\$)	Stock Awards (\$)	Securities Underlying Options (#)	Option Awards/ Adj. (\$)	Non-Equity Incentive Plan Compensation (\$)	All Other Compensation (\$)	Total (\$)
<b>DR. SEHAT SUTARDJA, PH.D.</b>									
Chairman, President and CEO	2013	841,346	-	3,040,000	/	8,751,750	-	1,517	12,634,613
Chairman, President and CEO	2012	783,076	-	-	/	11,324,040	180,000	283,056	12,570,172
Chairman, President and CEO	2011	691,731	1,200,000	6,489,747	/	2,443,275	-	5,186	10,829,939
Chairman, President and CEO	2010	657,000	985,000	-	/	-	-	574	1,642,574
Chairman, President and CEO	2009	88,443	-	-	/	2,162,230 <sup>16</sup>	-	30,600	2,281,273 <sup>17</sup>
Chairman, President and CEO	2008	533,435	-	-	/	7,254,923 <sup>18</sup>	13,500	12,267	7,814,125 <sup>19</sup>

20 <sup>16</sup> According to Marvell's 2010 proxy statement, page 32, the value of these  
 21 option awards was revised in 2010 to \$1,874,256 to reflect a new grant date fair value  
 22 in accordance with revised SEC disclosure requirements. The amounts do not  
 23 represent the actual amounts paid to or realized by the named executive officer.

24 <sup>17</sup> This total compensation figure was adjusted by Marvell in 2010 to \$1,993,299,  
 25 as stated in the Company's 2010 proxy statement. The adjustment was again made to  
 26 conform to new SEC disclosure requirements.

27 <sup>18</sup> According to Marvell's 2010 proxy statement, page 32, the value of the option  
 28 awards was revised to \$2,529,354 to reflect a grant date fair value in accordance with  
 29 new revised SEC disclosure requirements. The amounts do not represent the actual  
 30 amounts paid to or realized by the named executive officer.

31 <sup>19</sup> Total compensation adjusted to \$3,088,556 in the 2010 proxy statement to  
 32 reflect new SEC disclosure rules.

1	Position	Fiscal Year	Salary (\$)	Bonus (\$)	Stock Awards (\$)	Securities Underlying Options (#)	Option Awards/Adj. (\$)	Non-Equity Incentive Plan Compensation (\$)	All Other Compensation (\$)	Total (\$)
2	Chairman, President and CEO	2007	557,000 <sup>20</sup>	-	/	/	9,704,258	/	25,000	10,286,258 <sup>21</sup>
3	Chairman, President, CEO	2006	500,000	58,750	/	-	/	/	1,000	559,750
4	Chairman, President and CEO	2005	500,000	36,000	/	-	/	/	500	536,500
5	Chairman, President and CEO	2004	500,000	21,750	/	1,500,000	/	/	-	2,021,750
6	Co-Chairman of the Board, President, CEO	2003	500,000	13,000	/	200,000	/	/	-	713,000
7	<b>WEILI DAI</b>									
8	President of Marvell Technology Group, Inc.	2013	510,000	-	Option to purchase common shares and RSU <sup>22</sup>	/	-	-	-	510,000
9	Employee of MSI and former Executive VP and COO	2012	510,000	400,000	Option to purchase common shares and RSU <sup>23</sup>	/	-	-	-	910,000

<sup>20</sup> According to Marvell in their 2008 proxy statement, page 29, the value was retroactively adjusted to \$566,397 and was made to the executives effective as of January 31, 2006.

<sup>21</sup> Total compensation figure was subsequently adjusted by Marvell to \$10,297,155, as stated in the 2008 proxy statement, to reflect new SEC rules.

<sup>22</sup> According to the 2013 proxy statement, page 50, the Audit Committee and Executive Compensation Committee approved the grant to Ms. Dai of (A) an option to purchase 450,000 common shares at fair market value on the date of grant and with service-based vesting 1/3 annually beginning on the second anniversary of the vesting commencement date, which was April 1, 2013, (B) 60,000 RSUs with service-based vesting that vest in full on April 1, 2014, and (C) 100,000 performance-based RSUs based on certain performance metrics for fiscal 2014. The value of such shares and RSU were not provided by Marvell.

<sup>23</sup> According to the 2012 proxy statement, at page 54, the Audit Committee and Executive Compensation Committee approved the grant to Ms. Dai of (A) an option to purchase 800,000 common shares at fair market value on the date of grant and with service-based vesting, (B) 80,000 RSUs with service-based vesting. The value of such shares and RSU were not provided by Marvell.

Position	Fiscal Year	Salary (\$)	Bonus (\$)	Stock Awards (\$)	Securities Underlying Options (#)	Option Awards/Adj. (\$)	Non-Equity Incentive Plan Compensation (\$)	All Other Compensation (\$)	Total (\$)
Employee of MSI and former Executive Vice President and COO	2011	500,000	480,000	Option to purchase common shares <sup>24</sup>	/	-	-	-	980,000
Employee of MSI and former Executive Vice President and COO	2010	480,000	450,000	Option to purchase 100,000 common shares and 30,000 RSUs as well as a RSU for 236,518 shares <sup>25</sup>	/	-	-	-	930,000
Employee of MSI <sup>26 27</sup>	2009	450,000	-	Option to purchase common shares <sup>28</sup>	/	-	-	-	450,000

18       <sup>25</sup> According to Marvell's 2010 proxy statement, page 40, the Audit Committee  
19 and Executive Compensation Committee approved the grant to Ms. Dai of (A) an  
20 option to purchase 100,000 common shares at fair market value on the date of grant  
21 and with time-based vesting, (B) a RSU award for 30,000 common shares with time-  
22 based vesting, and (C) RSU award for up to 236,518 common shares, with the number  
of shares to vest to be subject to the achievement of performance objectives related to  
growth in revenue of a specific business group in fiscal years 2011 and 2012, subject to  
a minimum level of such revenue growth over the two-year period. The value of such  
shares and RSU were not provided by Marvell.

<sup>26</sup> Marvell Semiconductor, Inc. (“MSI”) is a subsidiary of Marvell Technology Group, Inc.

27 Ms. Dai served as the Vice President of Sales for Communications and  
25 Consumer Business, Vice President, General Manager of Communications and  
Computing Business Unit of MSI.

26                   <sup>28</sup> According to the 2009 proxy statement, at page 38, Ms. Dai was granted by  
27 the executive compensation committee an option to purchase 200,000 common shares  
28 at fair market value on the date of grant. The value of such shares and RSU were not  
provided by Marvell.

1	Position	Fiscal Year	Salary (\$)	Bonus (\$)	Stock Awards (\$)	Securities Underlying Options (#)	Option Awards/Adj. (\$)	Non-Equity Incentive Plan Compensation (\$)	All Other Compensation (\$)	Total (\$)
2	Employee of MSI <sup>29</sup> and former Executive VP and COO <sup>30</sup>	2008	280,962	-	-	/	7,387,067	500	3,582	7,672,111
3	Executive Vice President and COO <sup>31</sup>	2007	481,000 <sup>32</sup>	-	/	/	6,888,798	/	4,000	7,373,798 <sup>33</sup>
4	COO, Secretary and Director	2006	375,000	250	/	-	/	/	1,000	376,250
5	Executive VP, Secretary and Director	2005	375,000	-	/	-	/	/	500	375,500
6	Executive VP, Secretary and Director	2004	375,000	-	/	1,000,000	/	/	-	1,375,000
7	Executive VP, Secretary and Director	2003	375,000	250	/	100,000	/	/	-	475,250
8	<b>PANTAS SUTARDJA</b>									
9	VP, Chief Technology Officer and Chief R&D Officer	2013	423,442	-	638,400	/	1,983,730	-	3,517	3,049,089
10	VP, Chief Technology Officer and Chief R&D Officer	2012	413,292	-	-	/	2,426,580	24,960	156,030	3,020,862
11										

29 Ms. Dai transitioned into a position as Director of Strategic Marketing and business Development of MSI. On May 31, 2008, Ms. Dai was appointed Vice President of Sales for Communications and Consumer Business of MSI.

30 Beginning in 2007, Ms. Dai officially resigned from her position as an executive officer of the Company as a result of her settlement agreement with the SEC relating to the options backdating scandal at Marvell. The SEC settlement barred Dai from serving as an executive officer of Marvell for five (5) years. However, Dai immediately was given a high-level position with Marvell and/or MSI, although the exact nature of her job title and role at Marvell was not disclosed in Marvell's proxy statements.

31 Ms. Dai resigned as Executive Vice President and Chief Operating Officer and from the board of directors on May 6, 2007.

32 According to Marvell's 2008 proxy statement, at page 29, the value has been retroactively adjusted to \$487,802 and was made to the executives effective as of January 31, 2006.

33 Total compensation adjusted to \$7,380,600 as stated in the 2008 proxy statement.

	Position	Fiscal Year	Salary (\$)	Bonus (\$)	Stock Awards (\$)	Securities Underlying Options (#)	Option Awards/ Adj. (\$)	Non-Equity Incentive Plan Compensation (\$)	All Other Compensation (\$)	Total (\$)
1	VP, Chief Technology Officer and Chief R&D Officer	2011	400,000	180,000	446,794	/	488,655	-	2,990	1,518,439
2	Technology Officer and Chief R&D Officer	2010	400,000	160,000	-	/	-	-	38,113	598,113
3	VP, Chief Technology Officer and Chief R&D Officer	2009	53,847	-	-	/	1,181,290 <sup>34</sup>	-	1,384	1,236,521 <sup>35</sup>
4	VP, Chief Technology Officer, Acting Chief Operating Officer, Chief R&D Officer	2008	383,077	-	-	/	3,157,548 <sup>36</sup>	24,500	2,017	3,567,142 <sup>37</sup>
5	Chief Technology Officer	2007	400,000 <sup>38</sup>	-	/	/	4,652,587	/	34,000	5,086,587 <sup>39</sup>
6	Chief Technology Officer and Director	2006	300,000	10,250	/	-	/	/	1,000	311,250
7	Chief Technology Officer and Director	2005	300,000	30,000	/	-	/	/	500	330,500

<sup>34</sup> In 2010, according to Marvell's 2010 proxy statement, at page 32, Marvell revised the reported value of the option awards to \$312,168 to reflect a new grant date fair value in accordance with revised SEC disclosure requirements. As is stated in the proxy statements, the amounts do not represent the actual amounts paid to or realized by the named executive officer.

<sup>35</sup> In 2010, according to Marvell's 2010 proxy statement, at page 32, Marvell revised the reported value of Dai's total 2009 compensation to \$367,399, again to reflect new SEC disclosure requirements regarding executive compensation.

<sup>36</sup> According to Marvell in their 2010 proxy statement, at page 32, the value of the option awards has been revised to \$1,073,993 to reflect grant date fair value in accordance with the revised SEC disclosure requirements. The amounts do not represent the actual amounts paid to or realized by the named executive officer.

<sup>37</sup> Total compensation adjusted to \$1,483,587 as stated in the 2010 proxy statement.

<sup>38</sup> According to Marvell in their 2008 proxy statement, at page 29, the value has been retroactively adjusted to \$405,385 and was made to the executives effective as of January 31, 2006.

<sup>39</sup> Total compensation adjusted to \$5,091,972 as stated in the 2008 proxy statement.

1	Position	Fiscal Year	Salary (\$)	Bonus (\$)	Stock Awards (\$)	Securities Underlying Options (#)	Option Awards/ Adj. (\$)	Non-Equity Incentive Plan Compensation (\$)	All Other Compensation (\$)	Total (\$)
2	Chief Technology Officer and Director	2004	300,000	18,000	/	660,000	/	/	-	978,000
3	VP and Director	2003	300,000	1,500	/	100,000	/	/	-	401,500

131. A substantial portion of this compensation was unjust and unearned because these Individual Defendants caused Marvell to willfully infringe CMU's patents. But for the willful infringement of CMU's patents, Marvell's revenues, earnings per share, and profit margins (both on an absolute basis and compared to its peers) would have been substantially lower. In the CMU litigation, CMU expert witness Lawton demonstrated, and the jury agreed, that Marvell realized an excess profit per infringed chip of between \$0.06 and \$.72. It was stipulated by the parties at trial that Marvell sold 2,338,280,543 chips that infringed CMU's patents from March 6, 2003 through the date of the trial in December 2012. The average price per chip was \$4.42 and the operating profit per chip was \$2.16, based on Marvell's sales data produced at trial. Expert witness Lawton calculated the excess profit per infringed chip of between \$0.06 and \$0.72 by looking at both the sales data and then comparing same to Marvell's gross margin, operating income, and excess profits from 2000 to 2013 of the chips that were sold by Marvell that infringed CMU's patents (the MNP and NLD chips), and found that Marvell made approximately a 59.6% profit on its gross margins. Based on this data and these calculations, Lawton concluded that Marvell received \$0.42 of "excess profits" from its sales of the chips. Relying in part on her calculations of the excess profits benchmark of \$0.42 per unit, the operating profit benchmark of \$0.06 to \$0.72 per unit, and considering other relevant factors, Lawton opined that a reasonable royalty that Marvell should have paid CMU was \$0.50 per chip. The jury agreed with Ms. Lawton, CMU's expert, and awarded CMU \$1.17 billion in damages.

1       132. This data and evidence demonstrates that Marvell's earnings, revenues,  
 2 profits and profit margins, earnings per share, and other metrics were materially  
 3 inflated during the relevant time period. As a result, the performance-based  
 4 compensation awarded by Marvell (acting through the Executive Compensation  
 5 Committee, composed of Defendants Gromer, Kassakian, and Krueger) to  
 6 Defendants Sehat and Pantas Sutardja, and to Weili Dai, was excessive, unearned,  
 7 unjust, and inequitable. Not only did such Defendants not earn the performance-  
 8 based compensation, but they procured it through dishonesty, fraud, and willful  
 9 infringement of CMU's patents. As a result, it would be inequitable for them to  
 10 retain the compensation, and such compensation should be returned to Marvell.

11       133. Marvell's policy regarding recoupment of bonuses following a  
 12 restatement also supports the fact that the above-referenced compensation is unjust,  
 13 unearned, and should be returned. Marvell has a policy that its CEO and CFO  
 14 should return bonuses if the company restates its financial results and the bonuses  
 15 would have been lower taking into consideration the restatement, and if the  
 16 disinterested members of the Board determine that the restatement was caused in  
 17 whole or part by gross recklessness or intentional misconduct of the CEO or CFO.  
 18 This policy acknowledges that it would be inequitable for the Company's officers to  
 19 retain bonuses or other compensation that would not have been earned, or which  
 20 would have been lower, due to reckless or intentional misconduct by the officer.  
 21 This policy supports disgorgement or return of the compensation of Sehat and  
 22 Pantas Sutardja and Weili Dai. The CMU judgment constitutes a *de facto*  
 23 restatement of Marvell's financial results since the \$1.17 billion judgment, as  
 24 indicated *supra*, was based directly on damages calculations by CMU's expert which  
 25 demonstrated that Marvell achieved artificially high profits, revenues, and earnings  
 26 per share directly as a result of its sales of the infringed chips.

27  
 28

## **THE THREAT TO THE PAYMENT OF DIVIDENDS TO MARVELL'S CURRENT SHAREHOLDERS**

134. In May 2012, Marvell announced the initiation of paying its first quarterly dividend of \$0.06 per share. Marvell's Board of Directors declared quarterly cash dividends of \$0.06 per share payable to holders of its common shares in each quarter of fiscal 2014 and in each of the last three quarters of fiscal 2013. As a result, Marvell paid cash dividends of \$29.9 million in the three months ended February 1, 2014, and during fiscal 2014 and 2013, Marvell paid a total of \$119.4 million and \$98.8 million, respectively.

135. On February 24, 2014, however, Marvell filed the following Form 8-K with the SEC disclosing that the CMU judgment has impaired or may impair its ability to pay future dividends to its shareholders:

On February 20, 2014, Marvell announced that it had declared the payment of its quarterly dividend of \$0.06 per share to be paid on March 27, 2014 to all shareholders of record as of March 13, 2014. Developments in the CMU litigation could affect Marvell's ability to pay the dividend on March 27, 2014 under Bermuda law, where Marvell is incorporated. In such event, the payment of the dividend could be delayed until such time as Marvell can meet statutory requirements under Bermuda law. The payment of future quarterly cash dividends is subject to, among other things, the best interests of its shareholders, its results of operations, cash balances and future cash requirements, financial condition, statutory requirements of Bermuda law, and other factors that the board of directors may deem relevant.

136. On August 19, 2010, a year after being sued by CMU, the Individual Defendants caused Marvell to embark on a \$500 million stock repurchase plan. In short order, as the CMU litigation progressed, the Individual Defendants caused Marvell to quadruple the size of the plan to \$2 billion. By May 2012, Marvell had repurchased \$1.7 billion of the \$2 billion authorized repurchases. On May 17, 2012, Marvell authorized another \$500 million in repurchases of its own stock in a press release issued from its headquarters in Santa Clara, California which stated:

Marvell has repurchased approximately \$1.7 billion of its previously authorized \$2 billion program leaving about \$348 million remaining in the current repurchase program. With the new \$500 million authorization the total repurchase program increases to \$2.5 billion and

1 the amount remaining to \$848 million. Marvell has repurchased and  
 2 retired over 107 million shares, or about 16 percent, of the outstanding  
 3 shares since the initial announcement of the share repurchase program  
 4 in August 2010.

5 137. Analysts have been critical of the stock repurchase plan. Many have  
 6 noted that its announcement coincided with the CMU litigation.

7 138. On December 18, 2012, as the CMU litigation was nearing its end, the  
 8 Individual Defendants caused Marvell to increase the share repurchases by another  
 9 \$500 million.

10 139. The massive increases in the share repurchase program represents a  
 11 direct risk to, and infringement of, the shareholders' potential dividends. If Marvell  
 12 is forced to pay the CMU judgment, there will not be sufficient cash reserves at  
 13 Marvell to pay dividends. The Individual Defendants' wrongful conduct thus has  
 14 caused damage to the personal rights of Plaintiffs and the Class.

### 15 CLASS ACTION ALLEGATIONS

16 140. Plaintiffs bring this action on their own behalf and as a class action  
 17 pursuant to Federal Rule of Civil Procedure 23 on behalf of all holders of Marvell  
 18 stock who are being and will be harmed by defendants' actions described below (the  
 19 "Class"). Excluded from the Class are defendants herein and any person, firm, trust,  
 20 corporation, or other entity related to or affiliated with any defendant.

21 141. This action is properly maintainable as a class action.

22 142. The Class is so numerous that joinder of all members is impracticable.  
 23 According to Marvell's SEC filings, there were 503.4 million shares of Marvell  
 24 common stock outstanding as of March 20, 2014.

25 143. There are questions of law and fact that are common to the Class and  
 26 that predominate over questions affecting any individual Class member. The  
 27 common questions include, *inter alia*, the following:

28 (a) whether defendants have breached their fiduciary duties of undivided  
 29 loyalty, independence or due care with respect to Plaintiffs and the other members of

1 the Class as a result of their conduct with respect to the CMU's patents and the CMU  
 2 litigation;

3 (b) whether defendants' conduct has benefitted themselves to the detriment  
 4 of Plaintiffs and the Class;

5 (c) whether defendants' conduct threatens the dividends to be declared and  
 6 paid to Plaintiffs and the Class;

7 (d) whether defendants have breached any of their other fiduciary duties to  
 8 Plaintiffs and the other members of the Class in connection with their handling of the  
 9 CMU patents and CMU litigation, including the duties of good faith, diligence, candor,  
 10 and fair dealing; and

11 (e) whether Plaintiff and the Class are entitled to declaratory, injunctive,  
 12 and/or monetary relief, and if so the appropriate form and/or amount of such relief.

13 144. Plaintiffs' claims are typical of the claims of the other members of the  
 14 Class and Plaintiffs do not have any interests adverse to the Class.

15 145. Plaintiffs are adequate representatives of the Class, have retained  
 16 competent counsel experienced in litigation of this nature, and will fairly and  
 17 adequately protect the interests of the Class.

18 146. The prosecution of separate actions by individual members of the Class  
 19 would create a risk of inconsistent or varying adjudications with respect to  
 20 individual members of the Class which would establish incompatible standards of  
 21 conduct for the party opposing the Class.

22 147. Plaintiffs anticipate that there will be no difficulty in the management  
 23 of this litigation. A class action is superior to other available methods for the fair  
 24 and efficient adjudication of this controversy.

25 148. Defendants have acted on grounds generally applicable to the Class  
 26 with respect to the matters complained of herein, thereby making appropriate the  
 27 relief sought herein with respect to the Class as a whole.

## DERIVATIVE ALLEGATIONS

149. Plaintiffs also bring this action derivatively for the benefit of Marvell to  
 2 redress injuries suffered, and yet to be suffered, by Marvell as a direct and proximate  
 3 result of the Individual Defendants' breaches of fiduciary duty, violations of  
 4 California Corporations Code, waste of corporate assets and unjust enrichment.  
 5 Marvell is named in this action as a Nominal Defendant solely in a derivative  
 6 capacity.

150. Plaintiffs are current Marvell shareholders and have continuously held  
 2 Marvell stock at all relevant times.

151. Plaintiffs will fairly and adequately represent the interests of the  
 10 Company and have retained competent counsel, experienced in derivative litigation,  
 11 to enforce and prosecute this action.

152. This action is not a collusive one to confer jurisdiction on a court that it  
 13 would not otherwise have.

**I. The Derivative Claims are Authorized Under *Foss v. Harbottle*  
 15 Because Defendants' Wrongdoing has Infringed Upon the  
 16 Shareholders' Personal Rights**

153. Marvell is a Bermuda corporation. Bermuda follows the *Foss v.*  
 17 *Harbottle* decision, 2 Hare 461 (Eng. 1843), in determining the circumstances under  
 18 which a company's shareholders may maintain a derivative action. Under *Foss v.*  
 19 *Harbottle*, a derivative action may be maintained if the Individual Defendants'  
 20 wrongdoing infringes upon the personal rights of the company's shareholders, as  
 21 opposed to rights belonging to the company itself.

22 154. Here, the Individual Defendants' wrongdoing has infringed upon the  
 23 shareholders' personal rights because it has jeopardized the shareholders'  
 24 expectations and right to dividends. Dividends belong to the shareholders, not the  
 25 corporation. Thus, wrongdoing that impairs the company's ability to declare and  
 26 pay dividends infringes on the shareholders' personal rights.

27 155. On February 24, 2014 Marvell filed the following Form 8-K with the  
 28

1 SEC disclosing that the CMU judgment has impaired or may impair its ability to pay  
 2 future dividends to its shareholders:

3 On February 20, 2014, Marvell announced that it had declared the  
 4 payment of its quarterly dividend of \$0.06 per share to be paid on March  
 5 27, 2014 to all shareholders of record as of March 13, 2014.  
 6 Developments in the CMU litigation could affect Marvell's ability to pay  
 7 the dividend on March 27, 2014 under Bermuda law, where Marvell is  
 8 incorporated. In such event, the payment of the dividend could be  
 9 delayed until such time as Marvell can meet statutory requirements  
 under Bermuda law. The payment of future quarterly cash dividends is  
 subject to, among other things, the best interests of its shareholders, its  
 results of operations, cash balances and future cash requirements,  
 financial condition, statutory requirements of Bermuda law, and other  
 factors that the board of directors may deem relevant.

10 **II. The Derivative Claims are Authorized Under *Foss v. Harbottle*  
 Because Defendants' Conduct Was *Ultra Vires***

11 156. A shareholder derivative action is also authorized under the facts of the  
 12 present case because the Individual Defendants' conduct constitutes *ultra vires* acts,  
 13 which is another specific exception under *Foss v. Harbottle* permitting a derivative  
 14 claim. The directors and officers of Marvell were not permitted under Marvell's  
 15 Memorandum of Association<sup>40</sup> and Bye-Laws to willfully infringe CMU's patents.  
 16 Because they did so under circumstances constituting fraud and dishonesty, their  
 17 conduct constituted *ultra vires* acts.

18 157. The Individual Defendants also acted *illegally and unlawfully* by  
 19 causing the Company to willfully infringe patents owned by CMU, subjecting the  
 20 Company to a judgment in excess of \$1.54 billion.

21 158. The Individual Defendants also acted in a *dishonest manner* because  
 22 they lied to Marvell's shareholders about the Company's infringement of CMU's  
 23 patents, as alleged *supra*.

24 159. The Individual Defendants also acted in a *dishonest manner* because  
 25 they engaged in self-dealing. By willfully infringing CMU's patents and wrongfully

---

27 28 <sup>40</sup> Marvell's Memorandum of Association is the functional equivalent of Articles  
 of Incorporation.

1 refusing to pay royalties and/or licensing fees to CMU for the patents, the Individual  
 2 Defendants artificially increased Marvell's stock price and reported revenues and  
 3 earnings. As a result, and as detailed in this complaint, the Individual Defendants  
 4 wrongfully appropriated to themselves salaries, incentive-based compensation,  
 5 stock, stock options, bonuses, and other benefits that were unjust, unearned,  
 6 inequitable, and that should be returned to the Company.

7       160. As detailed above, Defendant Sehat Sutardja received several million  
 8 dollars in annual compensation for most years during the Relevant Period, with  
 9 annual compensation exceeding \$12.5 million for multiple years during this period;  
 10 Defendant Dai's substantial annual compensation included exceeding \$7 million for  
 11 multiple years during the Relevant Period; and Defendant Pantas Sutardja's  
 12 substantial compensation included several million dollars in annual compensation  
 13 for many years during the Relevant Period.

14       161. Moreover, Defendants Krueger, Gromer, Kassakian, and Thakur, all  
 15 Marvell outside directors, received hundreds of thousands of dollars in annual  
 16 compensation, including stock and option awards, during the relevant time period.  
 17 For example, Defendant Krueger's annual compensation was as high as \$636,665  
 18 during the Relevant Period; Defendant Gromer's annual compensation was as high  
 19 as \$320,905 during the Relevant Period; Defendant Kassakian's annual  
 20 compensation was as high as \$282,937 during the Relevant Period; and Defendant  
 21 Thakur's annual compensation was as high as \$238,903 during the Relevant  
 22 Period.<sup>41</sup>

---

23

24       <sup>41</sup> Defendant Krueger's compensation was \$490,020, \$636,665 (which includes  
 25 \$60,000 in Special Committee fees from the prior fiscal year), \$362,626, \$169,103,  
 26 \$208,561, \$264,700, and \$328,405 per year for the years 2007-2013, respectively.  
 27 Defendant Gromer's compensation was \$56,648, \$258,339, \$160,908, \$194,811,  
 28 \$249,700, and \$320,905 per year for the years 2008-2013, respectively. Defendant  
 Kassakian's compensation was \$91,106, \$135,730, \$164,811, \$194,700, and \$282,937  
 per year for the years 2007-2013, respectively. Defendant Thakur's annual  
 compensation for 2013 was \$238,903.

1       162. Through their actions, and with intent to benefit themselves at the  
 2 expense of the Company and its shareholders, the Individual Defendants engaged in  
 3 self-dealing and acting dishonestly, thus breaching their duties of good faith, fair  
 4 dealing, honesty and candor.

5       163. Marvell may not indemnify the Individual Defendants for their  
 6 wrongdoing since the wrongdoing involves dishonesty and/or fraud, as those terms  
 7 are used under Bermuda law. Article 30 of Marvell's Third Amended and Restated  
 8 Bye-Laws specifically states that Marvell may not indemnify any of its officers or  
 9 directors for "fraud or dishonesty which may attach to any of said persons."

10     **III. The Derivative Claims are Authorized Under *Foss v. Harbottle*  
 11           Because the "Fraud on the Minority" Exception Is Applicable**

12     164. As discussed above, the Individual Defendants have complete control  
 13 over Marvell. Defendants control over Marvell is manifested on at least three fronts.  
 14 First, Defendant Pantas Sutardja is the brother of Defendant Sehat Sutardja, and is  
 15 also one of the co-founders of Marvell. During the Relevant Period Pantas Sutardja  
 16 was a director, Vice President, Chief Technology Officer, and Chief R&D Officer at  
 17 Marvell. Collectively, Pantas Sutardja, his brother, and his brother's wife (Weili Dai,  
 18 who serves as Marvell's Vice President and General Manager of Communications  
 19 and Consumer Business) own and control approximately 19% of Marvell's stock.  
 20 Second, the Individual Defendants caused Marvell to ignore governance changes  
 21 recommended by the allegedly independent Board members, although Defendants  
 22 Sehat Sutardja and Weili Dai engaged in unethical and unlawful behavior. Third,  
 23 despite the settlement and her five-year ban on serving as an executive officer,  
 24 Defendant Dai continued to be generously compensated – even after her  
 25 "resignation" in 2007. And, as soon as Dai's five-year ban from serving as an  
 26 executive officer of Marvell expired, the Board promptly named Dai President of the  
 27 Company, effective July 14, 2013.

28     165. Indeed, year after year, the Individual Defendants were re-elected to

the Board based on Marvell's recommendations (made under their approval). All told, Marvell is run as a "family business" under the control of the Sutardja brothers and Dai.

166. As discussed above, the Individual Defendants committed fraud under the “fraud on the minority” exception by, among other things, (a) willfully causing Marvell to infringe upon CMU’s patents; (b) misrepresenting the use of CMU’s patents and the status of Marvell’s intellectual property and patents; (c) engaging in self-dealing by receiving performance-based compensation based on Marvell’s inflated revenues and profits resulting from the Individual Defendants’ misconduct; and (d) breaching their fiduciary duties owed to Marvell and its shareholders.

167. The Individual Defendants benefited from their wrongdoing set forth above. As a result, the “fraud on the minority” exception is applicable here.

**CAUSES OF ACTION  
Count I  
Breach of Fiduciary Duty  
Against All Individual Defendants**

168. Plaintiffs incorporate by reference and reallege each and every allegation contained above as if fully set forth herein.

169. The Individual Defendants owed and owe Marvell and its shareholders fiduciary obligations. By reason of their fiduciary relationships, the Individual Defendants owed and owe Marvell and its shareholders the highest obligation of good faith, fair dealing, loyalty and due care. Under Bermuda law, all of Marvell's officers and directors, in exercising their powers and discharging their duties, must act honestly and in good faith with a view to Marvell's best interests and exercise the care, diligence and skill that a reasonably prudent person would exercise in comparable circumstances.

170. The Individual Defendants violated their fiduciary duties of care, loyalty, and good faith, and acted in a dishonest manner, by engaging in one or more of the following acts: (a) causing or allowing the Company to willfully infringe

1 patents held by CMU; (b) disseminating to Marvell shareholders materially  
2 misleading and inaccurate information through, *inter alia*, SEC filings, press  
3 releases, and other public statements and disclosures as detailed herein; (c)  
4 approving or receiving compensation that was unjust and unearned because the  
5 compensation was based on revenues, earnings, and profits, which were inflated due  
6 to Marvell’s willful infringement of CMU’s patents; and (d) failing to reasonably  
7 settle the CMU litigation once liability became apparent. Further, each of the  
8 Individual Defendants failed to correct the Company’s publicly reported financial  
9 results and guidance. These actions could not have been a good faith exercise of  
10 prudent business judgment.

11        171. As a direct and proximate result of the Individual Defendants' breaches  
12 of fiduciary duties, Marvell and its shareholders have sustained significant damages,  
13 as alleged herein.

**Count II**  
**Breach of Fiduciary Duty**  
**for Failing to Maintain Adequate Internal Controls**  
**Against All Individual Defendants**

17       172. Plaintiffs incorporate by reference and reallege each and every  
18 allegation set forth above, as though fully set forth herein.

19       173. As alleged herein, each of the Individual Defendants had a fiduciary  
20 duty to, *inter alia*, exercise good faith to ensure that the Company had adequate  
21 internal controls. One of the most important internal controls at Marvell  
22 concerned patents and ensuring that Marvell did not infringe others' intellectual  
23 property and patents. As demonstrated in the CMU litigation, Marvell did not  
24 have effective internal controls concerning patents and/or did not follow its own  
25 internal policies concerning investigation of patents when it received notice of  
26 CMU's patents. Its failure to follow its own internal policies, or perform any  
27 investigation as to whether it was violated CMU's patents, was one of the reasons  
28 the jury found willful infringement by Marvell.

174. The Individual Defendants willfully ignored the obvious and pervasive problems with Marvell's internal controls and procedures and failed to make a good faith effort to correct the problems or prevent their recurrence.

175. As a direct and proximate result of the Individual Defendants' breaches of fiduciary duties, Marvell has sustained significant damages, as alleged herein.

**Count III**  
**Unjust Enrichment**  
**Against Defendants Sehat Sutardja, Pantas Sutardja, and Weili Dai**

176. Plaintiffs incorporate by reference and reallege each and every allegation set forth above, as though fully set forth herein.

177. By their wrongful acts and omissions, Defendants Sehat Sutardja, Pantas Sutardja, and Weili Dai were unjustly enriched at the expense, and to the detriment, of Marvell.

178. Plaintiffs, as shareholders and representatives of Marvell, seek restitution from such Defendants, and each of them, and seek an order of this Court disgorging all profits, benefits and other compensation obtained by such Defendants, and each of them, from their wrongful conduct and fiduciary breaches.

179. Plaintiffs, on behalf of Marvell, have no adequate remedy at law.

**Count IV**  
**Breach of Duty of Honest Services**  
**Against Defendants Sehat Sutardja, Pantas Sutardja, and Weili Dai**

180. Plaintiffs incorporate by reference and reallege each and every allegation contained above, as though fully set forth herein.

181. This claim is brought derivatively on behalf of the Company against Defendants Sehat Sutardja, Pantas Sutardja, and Weili Dai for breach of their undivided duty of loyalty to their employer, Marvell.

182. Defendants Sehat and Pantas Sutardja and Weili Dai were employees of Marvell.

183. As alleged above, Defendants Sehat and Pantas Sutardja and Weili Dai

breached their duty of loyalty to Marvell by not acting solely in Marvell's interests in performing their employment duties.

184. Those breaches of duty consisted of the conduct alleged throughout this complaint including, without limitation, Defendants' causing the Company to willfully infringe patents held by CMU, causing the Company to make false statements to the market that misrepresented the Company's patents, compliance with the law, business and financial prospects and by direct participation in willfully infringing CMU's patents. Defendants Sehat and Pantas Sutardja and Weili Dai benefitted from their wrongdoing because they received compensation that was directly tied to the company's financial performance.

185. Marvell was harmed by these Defendants' breaches of their undivided duty of loyalty.

186. By reason of the foregoing, Marvell was harmed and will continue to suffer harm as described in greater detail above.

## PRAYER FOR RELIEF

WHEREFORE, Plaintiffs pray for relief, as follows:

A. A judgment against all defendants and in favor of the Company, Plaintiffs, and the Class for the amount of damages sustained as a result of the defendants' breaches of fiduciary duties and other wrongdoing;

B. Directing Marvell to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable laws and to protect Marvell and its shareholders from a repeat of the damaging events described herein, including, but not limited to, putting forward for shareholder vote resolutions for amendments to the Company's By-Laws or Articles of Incorporation and taking such other action as may be necessary to place before shareholders for a vote the following Corporate Governance Policies:

(1) a proposal to strengthen the Board's supervision of operations and develop and implement procedures for greater shareholder input into the

1 policies and guidelines of the Board;

2 (2) a proposal to strengthen the Company's internal controls over  
3 patent laws and procedures to be followed to ensure that the Company  
4 does not infringe patents held by others;

5 (3) a provision to permit the shareholders of Marvell to nominate at  
6 least two candidates for election to the Board; and

7 (4) a proposal to strengthen the Company's procedures for the receipt,  
8 retention and treatment of complaints received by the Company  
9 regarding patents, accounting, internal controls and auditing matters.

10 C. Extraordinary equitable and/or injunctive relief as permitted by law and  
11 equity;

12 D. Awarding to Marvell restitution from the defendants, and each of them,  
13 and ordering disgorgement of all profits, benefits and other compensation obtained by  
14 the defendants due to the willful infringement of CMU's patents;

15 E. Awarding to Plaintiffs the costs and disbursements of the action,  
16 including reasonable attorneys' fees, accountants' and experts' fees, costs, and  
17 expenses; and

18 F. Granting such other and further relief as the Court deems just and  
19 proper.

20 ///

21 ///

22 ///

23 ///

24 ///

25 ///

26 ///

27 ///

28 ///

## **DEMAND FOR JURY TRIAL**

Plaintiffs hereby demand a trial by jury on all claims so triable.

Dated: August 15, 2014

Respectfully submitted,

BOTTINI & BOTTINI, INC.  
Francis A. Bottini, Jr. (175783)  
Yury A. Kolesnikov (271173)

s/ Francis A. Bottini, Jr.  
Francis A. Bottini, Jr.

7817 Ivanhoe Avenue, Suite 102  
La Jolla, California 92037  
Telephone: (858) 914-2001  
Facsimile: (858) 914-2002  
Email: [fbottini@bottinilaw.com](mailto:fbottini@bottinilaw.com)  
[ykolesnikov@bottinilaw.com](mailto:ykolesnikov@bottinilaw.com)

*Lead Counsel for Plaintiffs*

BERMAN DEVALERIO  
Christopher T. Heffelfinger (118058)  
Kristin A. Mattiske-Nicholls (288497)  
One California Street, Suite 900  
San Francisco, California 94111  
Telephone: (415) 433-3200  
Facsimile: (415) 433-6382  
Email: [cheffelfinger@bermandevalerio.com](mailto:cheffelfinger@bermandevalerio.com)  
[KMattiske-nicholls@bermandevalerio.com](mailto:KMattiske-nicholls@bermandevalerio.com)

Kristin J. Moody (206326)  
One Liberty Square  
Boston, Massachusetts 02109  
Telephone: (617) 542-8300  
Facsimile: (617) 542-1194  
Email: [kmoody@bermandevalerio.com](mailto:kmoody@bermandevalerio.com)

THE SHUMAN LAW FIRM  
Kip B. Shuman  
Rusty E. Glenn  
885 Arapahoe Avenue  
Boulder, Colorado 80302  
Telephone: (303) 861-3003  
Facsimile: (303) 484-4886  
Email: [kip@shumanlawfirm.com](mailto:kip@shumanlawfirm.com)  
[rusty@shumanlawfirm.com](mailto:rusty@shumanlawfirm.com)

*Counsel for Plaintiffs*

1 **CERTIFICATE OF SERVICE**

2 I hereby certify that on August 15, 2014, I authorized the electronic filing of the  
3 foregoing Verified Consolidated Shareholder Derivative Complaint with the Clerk of  
4 the Court using the CM/ECF system which will send notification of such filing to the  
5 e-mail addresses of the registered users.

6 I certify under penalty of perjury that the foregoing is true and correct.  
7 Executed on August 15, 2014 at La Jolla, California.

8 

---

9 s/ Francis A. Bottini, Jr.

10 Francis A. Bottini, Jr.

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

## VERIFICATION

I, Lee Voss, verify that I am a shareholder of Nominal Defendant Marvell Technology Group, Ltd. I have reviewed the allegations made in this Verified Consolidated Shareholder Derivative and Class Action Complaint (the "Complaint"). As to those allegations of which I have personal knowledge, I believe them to be true; as to those allegations of which I lack personal knowledge, I rely upon my counsel and counsel's investigation, and believe them to be true. Having received a copy of the Complaint and reviewed it with counsel, I authorize its filing.

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

Dated: August 12, 2014



Lee Voss

**VERIFICATION**

I, Sebastiano D'Arrigo, verify that I am a shareholder of Nominal Defendant Marvell Technology Group, Ltd. I have reviewed the allegations made in this Verified Consolidated Shareholder Derivative and Class Action Complaint (the "Complaint"). As to those allegations of which I have personal knowledge, I believe them to be true; as to those allegations of which I lack personal knowledge, I rely upon my counsel and counsel's investigation, and believe them to be true. Having received a copy of the Complaint and reviewed it with counsel, I authorize its filing.

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

Dated: August 12, 2014




Sebastiano D'Arrigo

**VERIFICATION**

I, James DiBiase, verify that I am a shareholder of Nominal Defendant Marvell Technology Group, Ltd. I have reviewed the allegations made in this Verified Consolidated Shareholder Derivative and Class Action Complaint (the "Complaint"). As to those allegations of which I have personal knowledge, I believe them to be true; as to those allegations of which I lack personal knowledge, I rely upon my counsel and counsel's investigation, and believe them to be true. Having received a copy of the Complaint and reviewed it with counsel, I authorize its filing.

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

Dated: August 13, 2014

  
\_\_\_\_\_  
James DiBiase

## VERIFICATION

I, Marie DiBiase, verify that I am a shareholder of Nominal Defendant Marvell Technology Group, Ltd. I have reviewed the allegations made in this Verified Consolidated Shareholder Derivative and Class Action Complaint (the "Complaint"). As to those allegations of which I have personal knowledge, I believe them to be true; as to those allegations of which I lack personal knowledge, I rely upon my counsel and counsel's investigation, and believe them to be true. Having received a copy of the Complaint and reviewed it with counsel, I authorize its filing.

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

Dated: August 13<sup>th</sup>, 2014



---

Marie DiBiase